## CUMULATIVE INDEX 1995

### Volume 79

<table>
<thead>
<tr>
<th>Month</th>
<th>Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>ENDOCRINE EMERGENCIES, pages 1–230</td>
</tr>
<tr>
<td>March</td>
<td>COMMON MEDICAL PROBLEMS IN AMBULATORY CARE, pages 231–462</td>
</tr>
<tr>
<td>May</td>
<td>ANTIMICROBIAL THERAPY I, pages 463–678</td>
</tr>
<tr>
<td>July</td>
<td>ANTIMICROBIAL THERAPY II, pages 679–949</td>
</tr>
<tr>
<td>September</td>
<td>CONTEMPORARY ISSUES IN CARDIOLOGY, pages 951–1270</td>
</tr>
<tr>
<td>November</td>
<td>OFFICE GYNECOLOGY, pages 1271–1529</td>
</tr>
</tbody>
</table>

**Note:** Page numbers of article titles are in **boldface** type.

Abdominal pain, lower, in pelvic inflammatory disease, 1280–1281
Abdominal sepsis, **599–617**. See also *Intra-abdominal sepsis.*
Abdominal signs, in bilateral massive adrenal hemorrhage, 114
Abdominal surgery, antibiotic prophylaxis for, 605–607
Abdominal trauma, penetrating, antibiotic prophylaxis for, 512, 519–520
Abnormal uterine bleeding, **329–344, 1357–1376**. See also *Uterine bleeding.*
Abortion, antibiotic prophylaxis for, 513
in first-trimester pregnancy, 1323–1324
management of, 1328–1329
Acetaminophen, for joint pain, 255–256
Acid-base disturbances, in diabetic ketoacidosis therapy, 27
*Aerobacter*, antibiotic susceptibility of, 681
Acne, clindamycin for, 852–853
Acquired immunodeficiency syndrome, and genital tract infections in women, 1290
weight loss in, 301
Activity restriction, for low back pain, 240
Adenosine, for pharmacologic stress echocardiography, 1045
Adhesiolysis, in chronic pelvic pain, 1422
Adrenal disease, benign vs malignant, characteristics of, 1489
classification of, 1483
Adrenal failure, confirmation of, 116–118
Adrenal hemorrhage, bilateral, massive, **107–129**
causes of, 109–111
clinical features of, 113–115
confirmatory tests in, 116–118
CT scan of, 117, 121
incidence of, 108
laboratory features of, 115
management of, 118–121
pathogenesis of, 112–114
prognosis in, 121–122
prospective diagnosis in, 116
risk factors in, 109–111
visualization of, 116
Adrenal medullary hyperplasia, and pheochromocytoma, 132–133
Adrenal necrosis, ACTH-mediated, and bilateral massive adrenal hemorrhage, 112
Adrenalectomy, for pheochromocytoma, 142–143
Adult respiratory distress syndrome, in diabetic ketoacidosis therapy, 26
Adverse drug reactions, to antimicrobials, 538–540
Aerobic gram-positive cocci, clindamycin spectrum of activity against, 848
Age, in nonketotic hypertonicity, 42
Age-related factors, and involuntary weight loss, 306
AIDS, weight loss in, 301
Albuminuria, in non-insulin-dependent diabetes mellitus, 295
Alcoholism, and involuntary weight loss, 307
Allergic reactions, to antibiotic therapy, 935–942
Alpha-adrenergic blocking agents, for pheochromocytoma, 143–144
Alteplase, for acute ischemic heart disease, 1013
Amantadine, dosing off in renal failure, 921
Amebiasis, metronidazole for, 863
Amenorrhea, definition off 1358–1359
Amikacin, chemical configuration of, 765
concentration in lower respiratory system, 586
gram-negative bacterial in vitro susceptibility to, 763
in hepatic disease, pharmacokinetics of, 904
in renal failure, dosing of, 921
Aminoglycoside(s), 761–787
adverse effects of, 540
adverse reactions to, 775–777
antimicrobial activity of, 762–765
antimicrobial synergy of, 766–767
chemical configurations of, 764–765
clinical use of, 777–779
concentration-dependent killing by, 489
curare-like effect of, 777
drug interactions with, 777
efficacy of, 779–781
empirc therapy with, 778–779
for intra-abdominal sepsis, 609–610
for obese patients, dosing weight correction factor for, 774
gram-negative bacterial resistance to, 767–768
historical information on, 761
intrarenal concentrations of, 632
laboratory monitoring of, 544
mechanism of action of, 767
microbiology of, 762–768
modifying factors in, 766
once-daily dosing of, 779–781
DREM in, 924–928
serum concentration in, 926
pharmacodynamics of, 768–769
clinical application of, 491
pharmacokinetics of, 769–775
absorption, 770
distribution, 770–771
elimination, 771–773
in hepatic disease, 904
therapeutic monitoring, 773–775
time or dose dependency, 770
plus antipseudomonal, for infections in immunocompromised host, 564–565
prophylaxis with, 777–778
safety profile of, 775–777
susceptibility testing of, 762
therapeutic alternatives to, 779–781
therapeutic concentrations of, 773
toxicity of, 780–781
Amiodarone, for atrial fibrillation, 1141, 1144
for sustained ventricular tachycardia, 1107
for ventricular fibrillation, 1107
for ventricular premature beats, 1099–1100
Amiodipine, cardiovascular actions of, 1075
for coronary artery disease with concomitant medical conditions, 1077
Amitriptyline, for migraine prophylaxis, 273
Amoxicillin, concentration in lower respiratory system, 586
Amoxicillin/clavulanic acid, in vitro activity and cost of, 698
indications for, 702
Amphotericin B, for fungal infections, 473
for infection in immunocompromised host, 574–575
Ampicillin, concentration in lower respiratory system, 586
in hepatic disease, 903
pharmacokinetics of, 905
with sulbactam, evaluation of, 471–472
in vitro activity and cost of, 698
indications for, 702
Anaerobes, clindamycin spectrum of activity against, 847–848
in intra-abdominal sepsis, treatment of, 608–609
metronidazole spectrum of activity against, 858, 860–861
Aneurysm, intracranial, headache associated with, 279
Angina pectoris, anti-ischemic drug therapy for, 1067–1068
in atherosclerosis regression trials, 987
pathophysiology of, 1064–1066
unstable, risk stratification in, 1053
Angiography, correlation with clinical coronary risk, 1247
Angiotensin-converting enzyme inhibitors, and chronic cough, 368–369
for acute ischemic heart disease, 1015
for heart failure, effects of, 1179–1181
studies of, 1177
for myocardial infarction, early administration of, safety of, 1199–1200
for postinfarction left ventricular dysfunction, 1196–1198
in left ventricular remodeling, experimental studies with, 1194–1196
in non-insulin-dependent diabetes mellitus, 295
Animal bite, antibiotic therapy for, in allergic patient, 937
Animal toxicity, of carbapenems, 750–751
Anion chelation, and hypocalcemia, 96–97
Anorgasmia, psychosexual nature of, 1303–1304
Antianaerobic, for infection in immunocompromised host, 575
Antianginal drugs, choice of, with concomitant medical conditions, 1077
for myocardial ischemia, efficacy of, 1076
general actions of, 1068
Antiarrhythmic therapy, for acute ischemic heart disease, 1016
for heart failure, 1183
for sustained ventricular tachycardia, 1107
Antibiotic(s). See also Antimicrobials.
antimicrobial action of, 477–478
concentrations in lower respiratory system, 586–587
efficacy of, concentration-activity determinants of, 497–499
failure of, 663–671
colonization vs infection, 667–668
drug fever, 668–671
in vivo vs in vitro susceptibility, 664–665
inadequate blood/tissue levels, 665–666
resistant organism, 668
spectrum and coverage problems, 664
tissue penetration problems, 666–667
untreatable infectious diseases, 667
for infections in immunocompromised host, modifications of, 571–576
for infective endocarditis, 1228–1233
for intra-abdominal sepsis, 607–612. See also Intra-abdominal sepsis.
for pneumonias, 581–597
for sepsis, 551–558
in hepatic disease, 895–917
in renal failure, dosing of, 919–933
changes in, 924–925
DREM system for, 920–922
intrarenal concentrations of, 632
kinetics and dynamics of, 477–495
minimum inhibitory concentration of, 486–488
oral, economic advantages of, 505
improved, 499–500
parenteral, indications for, 505–506
oral vs, 497–508
comparative clinical trials of, 500–505
partial renal elimination of, DREM in, 924
pathogen susceptibility to, in pyelonephritis, 625–627
pharmacodynamics of, 484–490. See also Pharmacodynamics.
pharmacokinetics of, 478–484. See also Pharmacokinetics.
prescribing of, considerations in, 537–549
prophylaxis with, 509–522
choice of, 510
for abortion, 513
for appendectomy, 512, 519
for cesarean section, 513
for clean surgical procedures, 512
for elective cholecystectomy, 512, 516
for elective colon resection, 512, 516–518
for gastric surgery, 515–516
for gastroduodenal surgery, 512
for hysterectomy, 512
for penetrating abdominal trauma, 512, 519–520
for prostatectomy, 513
for small intestine resection, 512, 518–519
for traumatic chest injuries, 520
for traumatic hemopneumothorax, 513
in commonly performed surgical procedures, 511
rules of, 509–511
timing of, 510–511
resistance to, 523–535. See also Antibiotic resistance.
selection of, for sepsis, 554–557
serum concentration-time curve for, one-compartment model of, 896
two-compartment model of, 898
therapy with, in allergic patient, 935–942
choice of, 936–941
manifestations of, 936
transitional therapy with, 469–471
Antibiotic formulary, 463–475
acquisition costs of, 464
administration costs of, 465
cost-benefit analysis in, 469
cost-effective strategies for, 541–545
designing of, 464–469
development of, 464–469
establishment of, steps in, 464
evaluation of, 471–472
future directions in, 474
outpatient, 472
restriction policies for, 468
staff recommendations for, 465
Antibiotic program, transitional, 466–468
Antibiotic resistance, of Streptococcus pneumoniae, 523–535
Antibiotic streamlining, 469–471
Anticholinergics, for irritable bowel syndrome, 383–384
Atrial fibrillation, mechanism of, 1146
for heart failure, 1183
Antidepressants, for chronic fatigue syndrome, 325
role in chronic pelvic pain, 1420
tricyclic, for premenstrual syndrome, 1465–1466
Antidiarrheals, for irritable bowel syndrome, 383
Antidiuretic hormone, regulation of, in critical illness, 215–216
syndrome of inappropriate secretion of, 161–162
Antifungal(s), for infection in immunocompromised host, 574–575
for intra-abdominal sepsis, 610–611
formulary for, 473–474
in hepatic disease, pharmacokinetics of, 904
Anti-HIV drugs, dosing of, in renal failure, 922
Antihypertensives, and impotence, 418–419
in coronary artery disease prevention, 991–992
Anti-infective agents, and hepatic disease, 895–917
pharmacokinetics in, 904–910
Anti-inflammatory agents, for low back pain, 241
Anti-ischemia drugs, for perioperative myocardial ischemia, 1255
Antimicrobial(s), adverse reactions to, 538–540
for elderly, approach to, 652–653
for infections in immunocompromised host, 568
patient compliance with, 539–541
prescribing of, considerations in, 537–549
control programs for, 545–547
cost-effective strategies for, 541–545
alternative dosing schemes, 542–543
rational laboratory monitoring, 543–545
switch to oral agents, 541–542
timely culture and sensitivity testing, 545
with good bioavailability, 542
Antinuclear antibody, in joint pain, 252–253
Antiplatelet therapy, for acute ischemic heart disease, 1012
Antithrombin therapy, for acute ischemic heart disease, 1013
Antiviral(s), for infection in immunocompromised host, 575
formulary for, 473–474
in hepatic disease, 903
pharmacokinetics of, 904
Anxiety, and chronic fatigue, 320
and involuntary weight loss, 307
Anxiolytics, for premenstrual syndrome, 1465
Aortic valve, dissection of, myocardial infarction vs, 1006
infective endocarditis of, complications with, 1224–1227
Appendectomy, antibiotic prophylaxis for, 512, 519
Arrhythmia(s), cardiac, physical findings suggestive of, 453
detection of, in syncope, 1166
mechanisms of, 1122–1123
Arterial insufficiency, and impotence, 421
Arthrocentesis, for joint pain, 250–251
Arthropathies, and low back pain, 234
Aspiration, and chronic cough, 370
Aspirin, for acute ischemic heart disease, 1011
low-dose, for migraine prophylaxis, 273
Asthma, cough-variant, and chronic cough, 365–366
Atenolol, doses and actions of, 1072
for premenstrual syndrome, 1466–1467
Atherosclerosis, coronary, prevention of, 973–998
See also Coronary artery disease; Coronary atherosclerosis
in non-insulin-dependent diabetes mellitus, 292
regression of, evidence for, 982–989
studies of, 983
lessons from, 988–989
with pharmacologic intervention, 984
Atrial fibrillation, 1135–1152
cardioversion for, 1140–1144. See also Cardioversion.
causes and clinical significance of,
1136–1137
clinical presentation of, 1137
conditions associated with, 1136
embolization in, prevention of,
1144–1147
effect of aspirin, 1145
primary, 1144–1145
role of transesophageal echocardiography, 1146–1147
secondary, 1146
warfarin vs aspirin, 1145
general approach to, 1138
mechanisms of, 1123
prevalence of, 1135–1136
rate control in, 1138–1140
beta-adrenergic blockers, 1139–1140
calcium channel blockers, 1139
digitalis, 1138–1139
Atrial flutter, catheter ablation of, 1127
mechanisms of, 1122–1123
Atrial natriuretic hormone, regulation of,
in critical illness, 217
Atrioventricular node, ablation of, for atrial fibrillation, 1147–1148
Atrioventricular node reentrant tachycardia, catheter ablation of, 1127
mechanisms of, 1122
Atrioventricular reciprocating tachycardia, mechanisms of, 1122
Azithromycin, 803–815
allergies to, alternatives for, 940
antimicrobial spectrum of, 804–805
clinical pharmacokinetics of, 805–809
clinical use of, 811–813
concentration in lower respiratory system, 586
experimental therapy with, 813
in hepatic disease, pharmacokinetics of, 909
in vitro activities of, 806–807
safety profile of, 809–811
Azlocillin, pharmacologic characteristics of, 683
AZT, in hepatic disease, pharmacokinetics of, 904–905
Aztreonam, 733–743
antimicrobial spectrum of, 733–734
clinical pharmacokinetics of, 734–738
clinical spectrum of, 739
clinical use of, 738–741
concentration in lower respiratory system, 587
concentrations in body fluids/tissues, 737
for infections in immunocompromised host, 567
in hepatic disease, pharmacokinetics of, 905
in vitro activity of, 735
safety profile of, 738

Babesiosis, clindamycin for, 854
Bacampicillin, concentration in lower respiratory system, 586
*Bacillus fragilis*, and intra-abdominal sepsis, 604
treatment of, 608–609
Bacteremia, aztreonam for, 740
cephalosporins for, 715
definition of, 551
source of, in infective endocarditis, 1210
Bacteria, anaerobic, and intra-abdominal sepsis, 603–604
gram-negative. See *Gram-negative bacteria*.
gram-positive. See *Gram-positive bacteria*.
Bacterial meningitis, carbapenems for, 754
in elderly, treatment of, 657–658
Bacterial prostatitis, quinolones for, 875–876
Bacterial vaginosis, clindamycin for, 853
metronidazole for, 863
Baker’s cyst, unilateral leg swelling in, 439
Basal body temperature graph, 332
Behavioral modification, for premenstrual syndrome, 1469
Bereavement, and involuntary weight loss, 307
Beta-adrenergic blockers, doses and actions of, 1072
for acute ischemic heart disease, 1014
for atrial fibrillation, 1139–1140
for coronary artery disease, 1071–1074
for migraine prophylaxis, 271–272
for perioperative myocardial ischemia, 1255
for pheochromocytoma, 144
for ventricular premature beats, 1099
general actions of, 1068
properties of, 1073
withdrawal symptoms with, 1073
Beta-lactam antibiotics, 745–759
- antipseudomonal, for infections in
  immunocompromised host, 564–566
- in hepatic disease, 903–911
  pharmacokinetics of, 905
- intrarenal concentrations of, 632
- susceptibility of gram-negative rods to, 681
Beta-lactamase inhibitor combinations, 695–704
- antimicrobial spectrum of, 697–699
- clinical pharmacokinetics of, 699–700
- clinical use of, 701–703
- indications for, 702
- safety profile of, 700–701
Beta-lactamase resistance, development of, 696
Betaxolol, doses and actions of, 1072
Bethesda system, of Papanicolaou smear
classification, 1429–1431
Bicarbonate therapy, for diabetic
ketoacidosis, 20–21
Bilateral massive adrenal hemorrhage, 107–129. See also Adrenal hemorrhage.
Biliary tract infection, empiric antibiotic therapy for, 556
Biposy curette, for endometrial biopsy, 1367
Bisphosphonates, for hypercalcemic crisis, 86
Bladder, pheochromocytoma of, 146
Bladder infection, empiric antibiotic therapy for, 556
Blurred vision, with Graves’s ophthalmopathy, 201
Bone/joint infections, aztreonam for, 741
- cephalosporins for, 713–714
- quinolones for, 880–881
Bone scanning, for low back pain, 238
Bowel habits, history of, in irritable bowel syndrome, 379
Bradydysrhythmia in myocardial infarction, 1007
Brain tumor, and headache, 280–281
Breast, anatomy of, 1443–1444
- benign masses of, 1444–1445
- cancer of. See Breast cancer.
Breast cancer, 1445–1447
- invasive, 1446–1447
- noninvasive, 1445–1446
- psychosexual gynecology in, 1314–1317
- risk factors for, 1447
- with hormone replacement therapy, 1341
- with oral contraceptives, 1385–1386
Breast disease, 1443–1455
- benign masses, 1444–1445
- cancer, 1445–1447. See also Breast cancer.
- mastalgia, 1447–1448
- nipple discharge, 1448–1450
- nonpalpable mammographic abnormalities, 1450–1451
- palpable masses, 1451–1452
- screening recommendations for, 1452–1453
Bromocriptine, for premenstrual syndrome, 1465
Bronchial hyperresponsiveness, postviral, and chronic cough, 369
Bronchiectasis, and chronic cough, 367–368
Bronchitis, chronic, and chronic cough, 367–368
Bundle branch block, in myocardial infarction, 1007
Bundle branch reentry ventricular tachycardia, catheter ablation for, 1110–1111
- with dilated cardiomyopathy, 1110
Caffeine restriction, for premenstrual syndrome, 1467–1468
Calcitonin, for cancer-related hypercalcemia, comparative trials of, 88–89
- for hypercalcemic crisis, 85–87
Calcium, accretion of, and hypocalcemia, 97
- normal homeostasis of, 80
- oral preparations of, 102
- plasma, regulation of, 93–94
- serum, hormonal control of, 81
Calcium channel blockers, cardiovascular actions of, 1075
- for acute ischemic heart disease, 1016
- for atrial fibrillation, 1139
- for coronary artery disease, 1074–1075
- for heart failure, 1182–1183
- for migraine prophylaxis, 272
- for pheochromocytoma, 143
- general actions of, 1068
Calorigenesis, in myxedema coma, 185
Cancer, weight loss in, 301, 303
- with oral contraceptives, 1385–1386
Candida albicans, vaginal infection with, 1276
Candidiasis, vulvovaginal, treatment regimens for, 1277
Capsaicin, for cluster headache, 276
Carbapenems, 745-759
adverse effects of, 540
adverse reactions to, 750-753
animal toxicity of, 750-751
antimicrobial spectrum of, 746-747
central nervous system reactions to, 751
clinical pharmacokinetics of, 746
clinical use of, 753-756
dosing recommendations for, 749-750
gastrointestinal reactions to, 751-752
hypersensitivity reactions to, 752
laboratory adverse experiences with, 752-753
metabolism of, 746-748
plasma kinetics, elimination, and tissue penetration of, 748-749
renal safety of, 752
Carbenicillin, in hepatic disease, pharmacokinetics of, 905
indanyl, indications, dosing, and preparations of, 684
pharmacologic characteristics of, 683
Carbohydrate, metabolism of, in diabetic ketoacidosis, 13
regulation of, in myxedema coma, 186-188
Carbon dioxide retention, in myxedema coma, factors leading to, 187
Carboxypenicillins, antipseudomonal, antimicrobial spectrum of, 680-682
Carcinoma in situ, cervical, prevalence of, 345-346
Cardiac arrhythmias, physical findings suggestive of, 453
Cardiac disorders, and involuntary weight loss, 305
Cardiac manifestations, in infective endocarditis, 1218
Cardiomyopathy, dilated, bundle branch reentry ventricular tachycardia with, 1110
idiopathic, nonsustained ventricular tachycardia in, 1103-1104
hypertrophic, nonsustained ventricular tachycardia in, 1104-1105
Cardiopulmonary sleep studies, indications and standards for, 410
Cardiovascular changes, in myxedema coma, 186
Cardiovascular death, 982, 1198
in atherosclerosis regression trials, 987
Cardiovascular disease, prevention of, with hormone replacement therapy, 1340
with oral contraceptives, 1385
Cardioversion, for atrial fibrillation, 1140-1144
electrical, 1147
exclusion criteria for, 1148
pharmacologic, 1140-1144
amiodarone, 1141, 1144
disopyramide, 1141-1143
flecainide, 1141, 1143
procainamide, 1141-1142
propafenone, 1141, 1143
quinidine, 1140-1142
sotalol, 1141, 1143-1144
predictors of success in, 1140
surgical, 1147-1148
Cardiovertor defibrillator, for sustained ventricular tachycardia, effect on mortality, 1108
Carotid massage, for arrhythmia detection, in syncope evaluation, 1158-1160
Catecholamines, blocking of, in pheochromocytoma, 143-144
in critical illness, 213-214
in diabetic ketoacidosis, 11
Catheter ablation, for sustained ventricular tachycardia, 1109-1114
bundle branch reentry type, 1110-1111
idiopathic type, 1111-1113
with coronary artery disease, 1113-1114
Cefaclor, concentration in lower respiratory system, 587
Cefadoxil, concentration in lower respiratory system, 587
Cefamandole, concentration in lower respiratory system, 587
Cefazolin, concentration in lower respiratory system, 587
Cefepime, 721-732
antimicrobial spectrum of, 721-723
clinical use of, 729
comparative antimicrobial activity of, 724
dosing recommendations for, 725
in vitro activity of, 722
pharmacokinetics of, 725-728
potential resistance of, 723-725
safety profile of, 728-729
structure and urinary metabolites of, 728
therapeutic alternatives to, 730
Cefizoxime, concentration in lower respiratory system, 587
Cefonicid, concentration in lower respiratory system, 587
Cefoperazone, adverse effects of, 711
clinical use of, 716
comparative antimicrobial activity of, 724
Cefoperazone (Continued)
concentration in lower respiratory system, 587
for infections in immunocompromised host, 566
in vitro activity of, 735
pharmacokinetics of, 726
in hepatic disease, 905
spectrum of activity of, 708–709

Cefotaxime, adverse effects of, 711
allergy to, alternatives for, 939
clinical use of, 712–715
comparative antimicrobial activity of, 724
concentration in lower respiratory system, 587
in vitro activity of, 735
parenteral vs oral, comparative clinical trials of, 501
pharmacokinetics of, 726
in hepatic disease, 906
resistance to, of *Streptococcus pneumoniae*, 527
spectrum of activity of, 708–709

Cefuroxime, concentration in lower respiratory system, 587

Central nervous system, infections of, 741
aztreonam for, 713, 715
infective endocarditis manifestations in, 1219
reactions to carbapenems, 751
Central pontine myelinosis, and hyponatremia, 164

Cephalothin, concentration in lower respiratory system, 587

Cephalexin, concentration in lower respiratory system, 586

Cephalosporin(s), adverse effects of, 540
allergy to, alternatives for, 939
for infections in immunocompromised host, 566
fourth-generation, comparative antimicrobial activity of, 724
pharmacokinetics of, 726
susceptibility breakpoints for, 723
parenteral vs oral, comparative clinical trials of, 501
surgical prophylaxis with, 510
third-generation, 705–719
adverse effects of, 711
antimicrobial spectrum of, 705–707
clinical use of, 712–717
comparative antimicrobial activity of, 724
dosing recommendations for, 709
in vitro activity of, 735
pharmacokinetics of, 707–709, 726
route of administration of, 706
safety profile of, 710–712
spectrum of activity of, 708–709
structure of, 706
susceptibility breakpoints for, 723
therapeutic alternatives to, 716–717

Cephalothin, concentration in lower respiratory system, 587

Cephadrine, concentration in lower respiratory system, 587

Cerebral edema, in diabetic ketoacidosis therapy, 25–26
Cerebral salt-wasting, and volume-contracted hyponatremia, 159
Cerebrovascular disease, and headache, 279–280
Cervical cancer, epidemiology and natural history of, 346–347
invasive, survival in, 346
management of, 1434
prevalence of, 345–346
screening for, 347–349
with oral contraceptives, 1386
Cervical caps, for contraception, 1391–1392
Cervical cytology, classification of, 350
clinical management of, 351
Cervical dysplasia, prevalence of, 345–346
Cervicitis, pelvic inflammatory disease with, 1278
vaginal discharge with, 1277–1280
Cervix, colposcopy of, 1433–1434
conization of, 1435
lesions of, and uterine bleeding, 1365
Cesarean section, antibiotic prophylaxis for, 513
Chancre, syphilitic, in woman, 1284
Chanroid, in women, 1286
Charcoal plasmaperfusion, for thyroid storm, 178
Chest injuries, traumatic, antibiotic prophylaxis for, 513
Chlamydia trachomatis, cervicitis with, 1277
infections with, treatment regimens for, 1280
Chloramphenicol, in hepatic disease, 911–912
pharmacokinetics of, 907
Chlorpromazine, for migraine headache, 270
Cholecystectomy, elective, antibiotic prophylaxis for, 512, 516
Cholecystitis, emphysematous, life-threatening, in diabetes mellitus, 59, 64–67
Cholesterol, as coronary risk factor, 964, 975
level of, in ischemic heart disease, 1003
lowering of, and atherosclerosis regression, 984–985
in coronary artery disease, 1065
Chromogranin A test, for pheochromocytoma, 139
Chronic cough, 361–372. See also under Cough.
Chronic fatigue, 315–327
causes of, medical, 317–320
psychiatric, 320
diagnostic approach to, 317
in primary care practice, 315–317
laboratory tests in, 319
syndrome of, 321–325
cause of, 322–324
CDC definition of, 321
management of, 324–325
symptom frequency in, 322
Chronic pelvic pain, 1411–1425. See also Pelvic pain.
Ciprofloxacin, concentration in lower respiratory system, 587
concentration ratios for, 499
for community-acquired pneumonia, 470
for febrile neutropenia, effectiveness of, 569
parenteral vs oral, comparative clinical trials of, 501
pharmacokinetics of, 873
in hepatic disease, 907
spectrum of in vitro activity of, 872
susceptibility of gram-negative rods to, 681
Clarithromycin, 803–815
allergy to, alternatives for, 940
antimicrobial spectrum of, 804–805
clinical use of, 811–813
experimental therapy with, 813
in vitro activities of, 806–807
pharmacokinetics of, 805–809
in hepatic disease, 909
safety profile of, 809–811
Clearance, of antibiotics, 480–481
Clindamycin, 845–867
adverse effects of, 540, 848–850
allergic reactions to, 849
concentration in lower respiratory system, 586
dosage and route of administration, 854–855
drug interactions with, 850
in hepatic disease, 912–913
pharmacokinetics of, 907
indications for, 850–854
acne, 852–853
babesiosis, 854
bacterial vaginosis, 853
decubitus ulcers, 852
diabetic foot ulcers, 852
dermatitis herpetiformis, 853
dermatologic infections, 853
endocarditis prophylaxis, 853
endometritis, 853
head and neck surgery, 853
intra-abdominal infections, 850–851
malaria, 854
odontogenic infections, 851–852
osteomyelitis, 853
pelvic infections, 851
Pneumocystis carinii infections, 854
skin/soft tissue infections, 852
Toxoplasma infections, 854
upper respiratory tract infections, 851
mechanisms of activity and resistance, 847
pharmacology of, 845–847
spectrum of activity of, 847–848
structure of, 845–846
use in pregnancy and nursing mothers, 855
Clodronate, for cancer-related hypercalcemia, comparative trials of, 88–89
Clonidine suppression test, for pheochromocytoma, 137–138
Clostridium difficile diarrhea, metronidazole for, 861
Clue cells, with bacterial vaginosis, 1275
Cluster headache, 274–277
diagnostic criteria for, 274
treatment of, 275–277
acute, 275–276
prophylactic, 276–277
Coagulopathy(ies), and bilateral massive adrenal hemorrhage, 111
and uterine bleeding, 1362
menorrhagia in, 332–333
Cocaine, for cluster headache, 275
Coccobacilli, on Papanicolaou smear, management in, 353
Codeine, for chronic cough, 363
Colon, infection of, empiric antibiotic therapy for, 556
motility of, alterations in, in irritable bowel syndrome, 376
resection of, elective, antibiotic prophylaxis for, 512, 516–518
Compromised host, infections in, empiric therapy for, 559–580. See also Immunocompromised host.
Computed tomography, of intra-abdominal sepsis, 604
scanning with, for low back pain, 237
single-photon emission, 1029–1030
Concentration-dependent killing, of antibiotics, 488–489
Concentration-independent killing, of antibiotics, 489–490
Concentration-time profile, dosage regimen and, 491
Condoms, for contraception, 1391
Condylomata acuminata, in women, 1287–1289
Condylomata lata, in woman, 1285
Congestive heart failure, death from, 1198.
See also Heart failure.
Conjunctiva, in Graves’s ophthalmopathy, 197
Connective tissue disease, and chronic fatigue, 318
and involuntary weight loss, 305
Constipation, medications causing, 380
Continuous infusion, of antibiotics, 483–484, 492
Contraception, 1377–1409
barrier methods of, 1390–1392
condoms, 1391
diaphragms and cervical caps, 1391–1392
spermicides, 1392
hormonal, 1381–1390
management of women using, 1390
oral contraceptives, 1381–1386. See also Oral contraceptives.
implants for, 1389–1390
composition and formulation, 1389
efficacy of, 1389
mechanism of action of, 1389
risks and benefits of, 1390
side effects of, 1390
in perimenopause, 1344
injectable, 1386–1388
composition and formulation of, 1387
health benefits of, 1388
mechanisms of action of, 1387
risks of, 1388
side effects of, 1387–1388
intruterine devices, 1392–1396
efficacy of, 1393
types and mechanisms of action, 1393
lactational, 1397–1398
methods of, prevalence of, 1378
patient selection issues in, 1398–1402
anticonvulsant medications, 1401
compliance, 1398
fetal risk, 1402
hypertensive women, 1399
postabortion, postpartum, and lactating women, 1402
women with coagulation disorders, 1400
women with contraindications to oral contraceptives, 1399
women with coronary artery disease, 1399
women with diabetes, 1400–1401
women with dyslipidemia, 1401
women with liver, gallbladder, and intestinal disease, 1401
women with mitral valve prolapse, 1399
periodic abstinence, 1396–1397
postcoital, 1380–1381
surgical sterilization, 1379–1380
withdrawal, 1398
Cornea, exposure of, with Graves’s ophthalmopathy, 203
Coronary angioplasty, 1085–1095
percutaneous transluminal, benefit of, 1088–1092
complete vs incomplete revascularization with, 1091–1092
coronary artery bypass grafting vs, medical economics, 1085–1086
studies of, 1089–1092
cost of, 1086–1088
implications of, 1092–1093
in atherosclerosis regression trials, 987
Coronary artery bypass grafting, 1085–1095
benefits of, 1089
coronary angioplasty vs, 1089–1092. See also Coronary angioplasty.
implications of, 1092–1093
in atherosclerosis regression trials, 987
prior, importance in noncardiac surgery, 1242–1245

Coronary artery disease. See also Angina pectoris; Myocardial ischemia.
atherosclerotic, pathophysiology of, 974–975
prevention of, 973–998, 976–977
primary trials for, 977–978
beta-adrenergic blockers for, 1071–1074
calcium channel antagonists for, 1074–1075
combination therapy for, 1076
familial and genetic predisposition to, 961
in elderly, prevention of, 961–962
ischemic. See Ischemic heart disease.
multi-vessel/high-risk, detection of, 1040
multivariate risk profiles of, 963
prevention of, antihypertensive therapy in, 991–992
diet, exercise, and lifestyle in, 989–991
hormonal replacement therapy in, 992–993
implications in, 963–966
practical guidelines for, 993–994
secondary, 979
atherosclerosis regression in, 982–988
lipid-lowering therapy for, 980–982
strategies for, cost-effectiveness of, 993
risk factors in, 951–971
following myocardial infarction, 962–963
levels of, 966
modification of, 1067
prediction with, 964–965
update on, 951–971
secular trends in, 963
stable, 1063–1084
anti-ischemic therapy for, effect on
clinical outcome, 1076–1078
medical options in, 1066
stress imaging in, 1025–1061. See also Stress imaging.
treatment choice for, 1092–1093
ventricular tachycardia with, idiopathic,
catheter ablation for, 1113–1114
nonsustained, 1101–1103

Coronary evaluation, recent, importance in noncardiac surgery, 1245

Coronary flow reserve, tests of, 1043–1047
diagnosis, 1043–1045
prognosis, 1045–1046
viability, 1046–1047

Coronary heart disease. See Coronary artery disease.

Coronary risk assessment, for noncardiac surgery, 1241–1262
complication probability in, exercise
stress testing and, 1248–1250
surgical type and, 1247–1248
elective surgery benefits vs complications, 1252
long-term risk stratification in, 1256–1257
modified perioperative care for complication reduction, 1252–1253
postoperative pathophysiology modification, 1254–1256
preoperative clinical, 1245–1247
Corpus luteum, hemorrhagic, in first-trimester pregnancy, 1324–1325
Corticosteroids, for involuntary weight loss, 311
for low back pain, 241
Corticotropin therapy, and bilateral massive adrenal hemorrhage, 111
Cortisol, in critical illness, 212
Cost effectiveness, of acute ischemic heart disease management, 1017–1019
of stress echocardiography, 1050–1051
Cough, chronic, 361–372
angiotensin-converting enzyme inhibitor-induced, 368–369
aspiration and, 370
bronchiectasis and, 367–368
causes and treatments of, 364
chronic bronchitis and, 367–368
cough-variant asthma and, 365–366
gastroesophageal reflux and, 366–367
pathophysiology of, 361–362
postnasal drip and, 364
postviral bronchial
hyperresponsiveness and, 369
psychogenic, 370
pulmonary tumors and, 369
restrictive lung disease and, 369
therapy for, 362–363
pathologic, 362
Creatine kinase, elevation of, in myocardial necrosis, 1008–1009
Creatine phosphokinase, in joint pain, 254
Critical illness, endocrine response to, 211–224
Crohn’s disease, metronidazole for, 861
Curettes, for endometrial biopsy, 1367–1368
Cutaneous manifestations, in infective endocarditis, 1218
Cyproheptadine, for involuntary weight loss, 311
for migraine prophylaxis, 273
Cystic renal disease, pyelonephritis with, 644
Cystitis, interstitial, and chronic pelvic pain, 1416

Dapsone, in hepatic disease, pharmacokinetics of, 907
Decubitus ulcers, clindamycin for, 852
Delta waves, in supraventricular tachyarrhythmias, radiofrequency catheter ablation of, 1126
Dementia, and involuntary weight loss, 306
Depression, and chronic fatigue, 320 and involuntary weight loss, 307
Dermatomes, of lower extremity, 233
Dextromethorphan, for chronic cough, 363
for heart failure, 1175
for perioperative myocardial ischemia, 1255
Diphenhydramine, for chronic cough, 363
Dipyridamole, for pharmacologic stress echocardiography, 1045
Disopyramide, for atrial fibrillation, 1141-1143
Diuretics, for heart failure, effects of, 1178-1180
for premenstrual syndrome, 1466
Divalproex sodium, for cluster headache prophylaxis, 276
Dobutamine, for pharmacologic stress echocardiography, 1043-1044
Dosing in Renopathy by Easy-to-Use Multipliers (DREM) system, 920-922
Doxycline, antibiotic sensitivities of, 791
DREM (Dosing in Renopathy by Easy-to-Use Multipliers) system, 920-922
in once-daily dosing of aminoglycosides, 924-928
mathematical derivation of multipliers in, 933
simplification of, 922-924
Drug(s), hepatic elimination of, classification of, 901
in hepatic disease, capacity-limited, 902 clearance of, 897
hepatic, 899-901
systemic, 898-899
flow-dependent, 901-902
intermediate extraction ratio of, 902-903
teratogenic effects of, 1333
Drug fever, and antibiotic failure, 668-671
clinical features of, 670
medications associated with, 670
Drug utilization, evaluation process for, 471-472
Dyspareunia, psychosexual nature of, 1301-1302
Eagle index, of clinical coronary risk, 1246
Echocardiography, in infective endocarditis, 1220-1221
stress. See Stress echocardiography.
with pharmacologic stress testing, for preoperative coronary risk assessment, 1251-1252
Economic hardship, and involuntary weight loss, 307
Ectopic pregnancy, intrauterine devices and, 1394-1395
Elderly, infections in, 651-661
antimicrobial therapy for, 652-653
scope of, 651
specific, 653-658
treatment of, bacterial meningitis, 657-658
pneumonia, 654-655
urinary tract, 655-657
unique aspects of, 652
sleep problems in, 399-400
syncpe in, management of, 1168
Electrocardiogram, and left ventricular hypertrophy predictors, 960-961
for arrhythmia detection, in syncpe evaluation, 1158
prolonged, for arrhythmia detection, in syncpe evaluation, 1159-1160
Electrocardiography, for palpitations, 453-454
Electrolyte loss, in diabetic ketoacidosis, 13-15
Electromyelography, for low back pain, 238
Electrophysiologic studies, for arrhythmia detection, in syncope evaluation, 1159, 1161-1162
Elimination rate constant, of antibiotics, 482
Emphysematous cholecystitis, life-threatening, in diabetes mellitus, 59, 64-67
Emphysematous pyelonephritis, life-threatening, in diabetes mellitus, 59, 67-70
Employment screening, in low back pain, 243
Enalapril, for heart failure, studies of, 1177
Encephalopathy, hyponatremic, pathophysiology of, 163-164
Endocardial lesions, thrombotic, nonbacterial, and infective endocarditis, 1209-1210
Endocarditis, antibiotic therapy for, in allergic patient, 937
infective, 1205-1240. See also Infective endocarditis.
prophylaxis for, clindamycin for, 853
Endocervical cells, on Papanicolaou smear, management of, 1438
Endocrine disorders, and chronic fatigue, 319
and euvoletic hyponatremia, 159
and involuntary weight loss, 303-304
Endocrine response, to critical illness, 211-224
Endometrium, ablation of, indications for, 1372
atrophied, 1349
postmenopausal bleeding from, 1351-1352
Endometrium ( Continued)
biopsy of, indications for, 339–340
steps in, 1368
cancer of, with hormone replacement therapy, 1340–1341
Endophthalmitis, clindamycin for, 853
Endothelium, damage to, and infective endocarditis, 1209
role of, in ischemic heart disease, 1004
Energy metabolism, abnormalities of, and weight loss, 301
Enoxacin, concentration in lower respiratory system, 587
pharmacokinetic parameters of, 873
spectrum of in vitro activity of, 872
Enterobacter, antibiotic susceptibility of, 681
Enterococcus, and intra-abdominal sepsis, 603
treatment of, 609
Epinephrine, in critical illness, 213–214
Epstein-Barr virus, and chronic fatigue syndrome, 332
Ergotamine tartrate, for cluster headache, 275
for migraine headache, 265–266
Erythema nodosum, unilateral leg swelling in, 440–441
Erythrocyte sedimentation rate, in joint pain, 251–252
Erythromycin, allergy to, alternatives for, 940
concentration in lower respiratory system, 586
in hepatic disease, pharmacokinetics of, 909
in vitro activities of, 806–807
resistance to, of Streptococcus pneumoniae, 527
Escherichia coli, antibiotic susceptibility of, 681
in immunocompromised host, 562
Esmolol, doses and actions of, 1072
 Estradiol, replacement level of, in hormone replacement therapy, 1346–1347
Estrogen, for abnormal uterine bleeding, 1370
for pelvic prolapse, 1477
Etidronate, for cancer-related hypercalcemia, comparative trials of, 88–89
for hypercalcemic crisis, 86
Exchange transfusion, for thyroid storm, 178
Exercise, as coronary risk factor, 959, 989–991
for low back pain, 240–241
for premenstrual syndrome, 1468
Exercise stress testing. See Stress testing.
Eyelid retraction, with Graves’s ophthalmopathy, 196

Famciclovir, for viruses, 473
Fasciitis, necrotizing, life-threatening, in diabetes mellitus, 70
Fatigue, chronic, 315–327. See also Chronic fatigue.
Female, pelvic mass in, 1481–1493. See also Pelvic mass.
Fever, in bilateral massive adrenal hemorrhage, 114
in immunocompromised host, 559–561
in infective endocarditis, 1218
in thyroid storm, 173
Fibrinogen, as coronary risk factor, 957–958
Fibroids, and menorrhagia, 333
Fibrinolysis, joint pain in, 250
Flecainide, for atrial fibrillation, 1141, 1143
Fleroxacin, pharmacokinetics of, 873
in hepatic disease, 908
spectrum of in vitro activity of, 872
Fluconazole, for fungal infections, 473
Fluid(s), in nonketotic hypertonicity, 45–46
losses of, and volume-contracted hyponatremia, 158–159
in diabetic ketoacidosis, 13–15
therapy with, in hypercalcemic crisis, 84
Fluid status, regulation of, in critical illness, 215–217
Fluoroquinolones. See also Quinolones.
concentration-dependent killing by, 488, 498
for infections in immunocompromised host, 568–570
in hepatic disease, 913–914
pharmacokinetics of, 907
pharmacodynamics of, application in clinical practice, 491–492
pharmacokinetics of, 873
spectrum of in vitro activity of, 872
structure of, 870
Fluoxetine, for migraine prophylaxis, 273
Foam cells, in coronary atherosclerosis, 974
Foscarnet, dosing of, in renal failure, 922
Free fatty acids, in diabetic ketoacidosis, 11
Free water loss, and nonketotic hypertonicity, 41
Functional capacity, cardiac, evaluation of, for intermediate-risk surgical patients, 1247–1248
Fungi, and infective endocarditis, 1216–1217
Galactorrhea, 1449–1450
Gallbladder disease, with hormone replacement therapy, 1341
Gallium nitrate, for cancer-related hypercalcemia, comparative trials of, 88–89
for hypercalcemic crisis, 87
Gancyclovir, dosing of, in renal failure, 922
Gas gangrene, necrotizing, life-threatening, in diabetes mellitus, 70
Gastric surgery, antibiotic prophylaxis for, 515–516
Gastrocnemius muscle, rupture of medial head of, unilateral leg swelling in, 439–440
Gastrointestinal surgery, antibiotic prophylaxis for, 512
Gastroesophageal reflux, and chronic cough, 366–367
Gastrointestinal disease, and involuntary weight loss, 304–305
Gastrointestinal flora, and intra-abdominal sepsis, 600
Gastrointestinal fluid losses, and volume-contracted hyponatremia, 158–159
Gastrointestinal infections, quinolones for, 876–878
tetracyclines for, 799
Gastrointestinal reactions, to carbapenems, 751–752
to metronidazole, 859
Genital prolapse, symptoms associated with, 1474
Genital tract, infections of, in women, 1271–1298
evaluation for, 1272–1274
history, 1272
laboratory, 1273–1274
physical examination, 1272–1273
genital skin conditions, 1287–1290
human papillomavirus, 1287–1289
molluscum contagiosum, 1289
pediculosis pubis, 1289
scabies, 1289–1290
genital ulcers in, 1281–1287
chancroid, 1286
granuloma inguinale, 1286–1287
herpes, 1281–1283
lymphogranuloma venereum, 1286
syphilis, 1283–1286
human immunodeficiency virus and, 1290–1291
lower abdominal pain with, 1280–1281
prevention of, 1291–1292
vaginal discharge with, 1274–1280
Genital warts, in women, 1287–1289
Genitourinary infection, cephalosporins for, 713–715
empiric antibiotic therapy for, 556
Gentamicin, chemical configuration of, 764
concentration in lower respiratory system, 586
dosing of, in neonates, 772
in renal failure, 921
once-daily, serum concentration in, 927
gram-negative bacterial in vitro susceptibility to, 763
in hepatic disease, pharmacokinetics of, 904
Giardiasis, metronidazole for, 863
Glandular cell abnormalities, on Papanicolaou smear, management in, 357
Glomerular filtration rate, increase in, in hypercalcemic crisis, 85
Glucagon, in critical illness, 215
Glucocorticoids, for cancer-related hypercalcemia, comparative trials of, 89–90
in critical illness, 212–213
Glucose metabolism, 1–2. See also Hypoglycemia.
as coronary risk factor, 955–956
Glucose tolerance test, in non-insulin-dependent diabetes mellitus, 289
Gonadotrophin-releasing hormone analogs, for abnormal uterine bleeding, 1371
Gonorrhea, aztreonam for, 741
isolates of, antimicrobial resistance in, 1279
Gram-negative bacteria, aminoglycosides for, 762–763
in vitro susceptibility to amikacin, 763
in vitro susceptibility to gentamicin, 763
resistance to aminoglycosides, mechanisms of, 767–768
Gram-positive bacteria, aminoglycosides for, 763–765
Granulocytopenia, febrile, therapeutic approaches to, 573
Granuloma inguinale, in women, 1286–1287
Granulomatous diseases, and hypercalcemia, 82
Graves’s disease, clinical appearance of, 196
Graves’s hyperthyroidism, relationship to Graves’s ophthalmopathy, 206–207
Graves’s ophthalmopathy, 195–209
diagnosis of, 195–199
extraocular muscle enlargement in, 199
Graves’s ophthalmopathy (Continued)
imaging of, 199–200
manifestations of, urgent and emergent
care of, 199–203
relationship to Graves’s
hyperthyroidism, 206–207
treatment of, 203–206
surgical, 204, 206

Growth hormone, in critical illness,
214–215

Guaifenesin, for chronic cough, 363

Gynecology, psychosexual, 1299–1317. See
also Psychosexual gynecology.

Half-life, of antibiotics, 482–483
in hepatic disease, 896–897

Head and neck surgery, clindamycin for,
853

Headache(s), 261–286
brain tumor and, 280–281
cerebrovascular disease and, 279–280
cluster, 274–277. See also Cluster
headache.
intracranial aneurysm associated with,
279
migraine, 262–274. See also Migraine
headache.
miscellaneous, 279–281
temporal arteritis and, 280
temporomandibular disorders and, 281
tension, 277–279. See also Tension
headache.

Heart, functional capacity of, evaluation
of, for intermediate-risk surgical
patients, 1247–1248
wall motion in, echocardiography of,
1042

Heart disease, congenital, and infective
docarditis, 1207–1208
valvular, nonsustained ventricular
tachycardia in, 1105

Heart failure, 1171–1190
clinical pharmacotherapeutic trials in,
1176
controversial drugs for, 1182–1183
antiarrhythmics, 1183
anticoagulants, 1183
calcium channel blockers, 1182–1183
nonsteroidal anti-inflammatory drugs,
1183
death from, 1198
definition of, 1172
diagnosis of, 1173
end-stage, 1183–1184
left ventricular dysfunction with,
1191–1203
clinical importance of, 1193
early intervention in, 1201–1202
etiopathologic factors in, 1192–1193
natural history in, 1192–1193
postinfarction remodeling and,
1193–1196
pathophysiology of, and
pharmacotherapeutic focus, 1174
physiology of, relationship of therapies
to, 1173–1178
specific drug classes for, 1178–1182
angiotensin-converting enzyme
inhibitors, 1179, 1181
cardiac glycosides, 1181–1182
digoxin, 1179, 1181–1182
direct-acting vasodilators, 1180–1181
diuretics, 1178–1180
treatment strategies for, 1184–1187

Hemodynamics, abnormal, and infective
docarditis, 1209

Hemorrhagic diathesis, and bilateral
massive adrenal hemorrhage, 111–113

Heparin, for acute ischemic heart disease,
1012–1013

Hepatic clearance, of antibiotics,
480–481

Hepatic disease, altered drug disposition
in, 900
anti-infective agents and, 895–917
pharmacokinetics of, 904–910
antivirals in, 903
beta-lactams in, 903–911
chloramphenicol in, 911–912
clofibrate in, 912–913
fluoroquinolones in, 913–914
isoniazid in, 914
pharmacokinetic principles in, 896–903
capacity-limited drugs, 902
drug clearance, 897
flow-dependent drugs, 901–902
half-life, 896–897
hepatic clearance, 899–901
intermediate extraction ratio, 902–903
systemic clearance, 898–899
volume of distribution, 897–898
rifampin in, 914

Herpes, genital ulcers with, in women,
1281–1287

Herpes simplex, on Papanicolaou smear,
management in, 352

High density lipoprotein, as coronary risk
factor, 952–953, 964
Hirudin, for acute ischemic heart disease, 1013
HIV-positive women, cervical cytology in, 349
Homeostatic decompensation, in thyroid storm, treatment of, 178–179
Homocystine, as coronary risk factor, 958
Hormonal concerns, psychosexual gynecology in, 1312–1314
Hormone replacement therapy, 1345–1348
benefits of, 1340
candidates for, 1343
choice of hormones in, 1345–1346
estriol, blood levels in, 1346–1347, 1349
evaluation for, 1341–1343
history and physical examination, 1341–1342
imaging and biopsy, 1342
laboratory studies, 1342
for coronary artery disease prevention, 992–993
healthy lifestyle with, 1343
hormone level measurement in, 1347
institution of, 1348–1350
monitoring of, 1350
paradigm for, 1353
problems with, 1350–1353
bleeding, 1350–1351
hyperestrogenism, 1351
progesterone problems, 1353
progesterone, blood levels in, 1349
risks of, 1340–1341
routes of administration of, 1347–1348
Hot flashes, prevention of, with hormone replacement therapy, 1340
Human bite, antibiotic therapy for, in allergic patient, 937
Human chorionic gonadotropin, levels in normal pregnancy, 1321
Human immunodeficiency virus (HIV), and genitai tract infections in women, 1290–1291
and uterine bleeding, 1363
formulary of, 473–474
Human papillomavirus, Papanicolaou smear of, 1431–1433
Hungry bone syndrome, and hypocalcemia, 97
Hydralazine, for heart failure, effects of, 1180
studies of, 1175
Hydration, for cancer-related hypercalcemia, comparative trials of, 89
for diabetic ketoacidosis, 17–19
14-Hydroxycarathromycin, in vitro activities of, 806–807
Hypercalcemia, cancer-related, comparative trials in, 88–89
causes of, 82–83
equilibrium and disequilibrium, 80–82
malignancy and, 82
Hypercalcemic crisis, 79–92
clinical features of, 83
differential diagnosis of, 83–84
drugs for, 85
management of, 84–90
Hyperchloremic acidosis, in diabetic ketoacidosis therapy, 26–27
Hyperglycemia, in diabetic ketoacidosis, 12
Hyperinsulinemia, as coronary risk factor, 955
Hyperphosphatemia, with hypocalcemia, 396
Hyperpyrexia, in thyroid storm, 173
Hypersensitivity reactions, with clindamycin, 849
Hypersomnia, 402–407
categories of, 396
Hypersomnolence, causes of, 407
Hypertension, as coronary risk factor, 954–955, 964
control of, 991–992
Hyperthyroidism, and impotence, 420–421
and involuntary weight loss, 303–304
Hypertonicity, nonketotic, in diabetes mellitus, 39–52. See also Diabetes mellitus; Nonketotic hypertonicity.
Hypnotics, for insomnia, 400–402
pharmacokinetic properties of, 401
Hypocalcemia, causes of, 95–99
anion chelation, 96–97
calcium accretion, 97
critical illness, 99
enhanced protein binding, 95–96
parathyroid hormone deficiency/resistance, 97–99
vitamin D deficiency/resistance, 99
clinical approach to, 101
diagnostic evaluation of, 100
long-term therapy of, 100
emergencies in, 93–106
treatment of, 99–100
long-term therapy of, 100–103
severe, manifestations of, 94–95
Hypoglycemia, 1–8
clinical presentation of, 3
physiology of, 1–2
risk factors for, 2–3
sequelae of, 5–6
symptoms of, mechanisms of, 4
treatment of, 5
in myxedema coma, 191
Hypomagnesemia, with hypocalcemia, 100

Hyponatremia, approach to, 156-163
  brain adaptation to, 163-164
  development of, normal defenses against, 156
  emergencies in, 155-168
    treatment of, 165-166
  encephalopathy in, pathophysiology of, 163-164
  euvoletic, 159-161
  postoperative, 160
  signs and symptoms of, 163
  thiazide-associated, euvoletic, 160-161
    treatment of, 165-166
  in myxedema coma, 191
  volume-contracted, 158-159
  with edematous disorders, 161-163
  with hyperosmolality, approach to, 157-158
  with hypo-osmolality, approach to, 158-163
  differential diagnosis of, 157

Hypoparathyroidism, and hypocalcemia, 97-98

Hypotension, in bilateral massive adrenal hemorrhage, 115
  management of, 118-119
  in myxedema coma, treatment of, 191

Hypothalamic-pituitary-thyroid axis, thyroid hormone regulation by, 170

Hypothermia, treatment of, in myxedema coma, 190

Hypothyroidism, and impotence, 420-421
  treatment of, 423
  and involuntary weight loss, 304
  and joint pain, 253-254
  myxedema coma in, 185-194. See also Myxedema coma.

Hypoventilation, in myxedema coma, factors leading to, 187

Hysterectomy, antibiotic prophylaxis for, 512
  as surgical sterilization, 1379
  for abnormal uterine bleeding, 1372
  for chronic pelvic pain, 1423-1424
  Hysteroscopy, for abnormal uterine bleeding, 1372

Ibuprofen, for migraine headache, 265
  for tension headache, 278

Ileum infection, empiric antibiotic therapy for, 556

Illness, precipitating, in nonketotic hypertonicity, 42-43

Imipenem, antimicrobial spectrum of, 747
  concentration in lower respiratory system, 587
  dosing recommendations for, 749-750
  for infections in immunocompromised host, 567

Imipenem-cilastatin, comparative efficacy of, 755
  dosing regimens for, 750
  peripheral penetration of, 749
  pharmacokinetics of, 748
  in hepatic disease, 907

Immunocompromised host, infections in, 559-580
  antimicrobial therapy for, 564-570
  aminoglycoside plus antipseudomonal beta-lactam, 564-565
  combination beta-lactams, 565-566
  duration of, 571
  modifications of, 571-576
  antianaerobic added, 575
  antifungal added, 574-575
  antiviral added, 575
  trimethoprim/sulfamethoxazole added, 576
  vancomycin added, 572-574
  monotherapy, 566-570
  clinical picture in, 560-561
  defects accompanying, 559-560
  laboratory approach to, 563-564
  predominant pathogens in, 561-563
  pyelonephritis with, 644

Immunologic disorders, and chronic fatigue syndrome, 323

Immunosuppressed woman, abnormal Papanicolaou smear in, management in, 356-357

Impotence, 415-434
  arterial insufficiency and, 421
  drug-induced, 418-419
  treatment of, 423
  evaluation of, 416-422
  algorithm for, 429
  experimental therapy for, 428-430
  hormonal causes of, 419-421
  treatment of, 423
  neurologic disease and, 422
  physiology of, 415-416
  psychogenic, clinical characteristics of, 417
  evaluation of, 416-417
  treatment of, 422-423
  treatment of, 422-430
  algorithm for, 429
  vascular disease and, 421-422
  treatment of, 424

Indanyl carbenicillin, indications, dosing, and preparations of, 684

Indomethacin, for cancer-related hypercalcemia, comparative trials of, 89
Infection(s), and chronic fatigue, 317–318
and involuntary weight loss, 304
emergencies in, in diabetes mellitus, 53–77. See also Diabetes mellitus.
in compromised host, empiric therapy for, 559–580. See also Immunocompromised host.
in elderly, treatment of, 651–661. See also Elderly.
in myxedema coma, treatment of, 191
mixed, parenteral vs oral antibiotics for, 502

Infective endocarditis, 1205–1240
antibiotics for, 1228–1233
aortic valve, complications with, 1224–1226
clinical manifestations of, 1217–1219
culture-negative, 1217
definition of, 1205–1207
diagnostic studies in, 1220–1228
blood cultures, 1220
echocardiography, 1220–1221
Duke criteria for, 1206
experimental, pathogenesis of, 1208–1209
left-sided, echocardiography of, 1222–1228
indications for surgery, 1226
microbiology of, 1211–1217
mitral valve, complications with, 1226–1228
pathogenesis of, 1208–1210
pathophysiology of, 1210–1211
predisposing factors to, 1207–1208
prevention of, 1233–1234
right-sided, echocardiography of, 1221–1222
treatment of, 1228–1233

Infertility, psychosexual gynecology in, 1311–1312
Insomnia, 396–402
categories of, 396
circadian rhythm disturbances and, 398–399
conditioned, 398
hypnotic therapy for, 400–402
in elderly, 399–400
psychiatric disorders and, 397–398
restless leg syndrome and, 399
transient and short-term, 397
Insufficient sleep syndrome, and excessive sleepiness, 403–404
Insulin resistance, as coronary risk factor, 955–956
Insulin therapy, for diabetic ketoacidosis, 19
Interstitial cystitis, and chronic pelvic pain, 1416
Intra-abdominal sepsis, 599–617
animal model of, 601
antibiotic treatment of, 607–612
aminoglycosides, 609–610
antianaerobic, 608–609
antifungals, 610–611
aztreonam, 740–741
carbapenems, 753
clindamycin, 850–851
duration of, 611
one vs two drugs, 607–608
percutaneous drainage with, 612
recommended drugs for, 608
selection of, 607
diagnostic studies of, 604–605
microbiology of, 602–604
Enterococcus, 603
new anaerobic bacteria, 603–604
Pseudomonas aeruginosa, 602–604
natural history of, 599–602
gastrointestinal flora, 600
virulence factors in, 602
prophylaxis of, 605–607
Intrauterine device(s), and ectopic pregnancy, 1394–1395
and genital infections, 1394
and nongenital infections, 1394
and pelvic inflammatory disease, 1393–1394
and uterine bleeding, 1365
for contraception, 1392–1396. See also Contraception.
medical considerations with, 1395
patient selection for, 1396
Intravenous line infection, empiric antibiotic therapy for, 556
Intravenous line sepsis, cephalosporins for, 714–715
Involuntary weight loss, 299–313
iodine, inorganic, for thyroid storm, 177
Ipodate, for thyroid storm, 177
Irritable bowel syndrome, 373–390
definition and clinical presentation of, 374–375
diagnostic criteria for, 374
differential diagnosis of, 379, 381
epidemiology of, 375
evaluation of, 378–382
laboratory tests for, 381
management of, 382–385
medications for, 384
pathophysiology of, 375–377
psychosocial factors in, 377–378
Ischemic heart disease, acute, 999–1023
classification of, 1000–1001
cost-efficient management of, 1017–1019
length of stay in, 1017–1018
Ischemic heart disease (Continued)
provocative testing, 1018–1019
rapid diagnosis and risk stratification, 1017
diagnosis of, 1004–1008
electrocardiogram, 1005–1007
history, 1004–1005
physical examination, 1005
summary measures, 1007–1008
ischemic triggers in, 1003
nomenclature of, 999–1002
pathophysiology of, 1002–1004
serum markers in, 1008–1009
therapy for, 1009–1016
acute reperfusion, 1010–1011
angiotensin-converting enzyme inhibitor, 1015
antiarrhythmic, 1016
antiplatelet, 1011–1012
antithrombin, 1012–1013
beta-blocker, 1014
magnesium, 1016
nitrate, 1014–1015
pain relief, 1016
Isolation, and involuntary weight loss, 307
Isoniazid, in hepatic disease, 914
pharmacokinetics of, 908
Isosorbide dinitrate, for heart failure, effects of, 1180
studies of, 1175
Isotonic saline, for diabetic ketoacidosis, 18
Itraconazole, in hepatic disease, pharmacokinetics of, 904
Joint pain, 247–260
devices for, 257
diagnostic tests for, 250–255
antinuclear antibody, 252–253
arthrocentesis, 251
creatine phosphokinase, 254
erythrocyte sedimentation rate, 251–252
radiographs, 254–255
rheumatoid factor, 252
thyroid function, 253–254
uric acid, 254
general approach to patient, 249–250
history of, 247–248
physical examination in, 248–249
treatment issues in, 255–257
acetaminophen, 255–257
misoprostol, 256–257
nonsteroidal anti-inflammatory drugs, 256
Kanamycin, dosing of, in renal failure, 921
Kegel exercises, for pelvic floor musculature, 1477–1478
Keratitis, with Graves’s ophthalmopathy, 203
Ketoacidosis, diabetic, 9–37
Ketorolac, for migraine headache, 265, 269, 271
Kidney(s), antibiotic concentrations in, 632
bacterial invasion of, in ascending pyelonephritis, 628
infection of, empiric antibiotic therapy for, 556
Klebsiella, antibiotic susceptibility of, 681
Labetolol, doses and actions of, 1072
Lactam antibiotics, concentration-independent killing by, 490, 498
half-lives of, 500
pharmacodynamics of, application in clinical practice, 492
Lactational contraception, 1397–1398
Laparoscopy, diagnostic, in chronic pelvic pain, 1421–1422
Left ventricle, dysfunction of, heart failure with, 1191–1203. See also Heart failure.
postinfarction, angiotensin-converting enzyme inhibitor trials for, 1196–1198
ejection fraction of, in dynamic exercise stress echocardiography, 1040
function of, preoperative coronary risk assessment of, 1252
hypertrophy of, predictors of, 960–961
postinfarction remodeling of, and cardiac dysfunction, 1193–1194
role of nitrates in, 1200
Leg, unilateral swelling of, 435–447
acute-onset, 438–441
acute deep venous thrombosis, 438–439
cellulitis, 440
erythema nodosum, 440–441
popliteal cyst, 439
rupture of medial head of gastrocnemius muscle, 439–440
causes of, 436
chronic, 441–446
chronic venous insufficiency, 441–442
congenital venous malformations, 445
lymphedema, 442–444
malignancy, 445–446
reflex sympathetic dystrophy, 444–445
history and physical examination in, 435–438
Legionella, and nosocomial pneumonia, 592
Leiomyomata, pelvic, 1485
Leukocyte count, as coronary risk factor, 956–957
Lidocaine, for cluster headache, 275
Lifestyle, and chronic fatigue, 320
as coronary risk factor, 959–960, 989–991
Limb movements, periodic, and insomnia, 399
Lipid(s), as coronary risk factor, 952–954
metabolism of, in diabetic ketoacidosis, 13
Lipid hypothesis, in coronary atherosclerosis, 975–976
Lipid-lowering therapy, for secondary prevention of coronary artery disease, 980–982
Lithium carbonate, for cluster headache prophylaxis, 276
for thyroid storm, 177
Liver, anti-infective agents and, 895–917
cancer of, with oral contraceptives, 1386
infection of, empiric antibiotic therapy for, 556
Local reactions, with clindamycin, 849
Lomefloxacin, pharmacokinetic parameters of, 873
spectrum of in vitro activity of, 872
Low back pain, 231–246
classification of, 232–234
diagnostic strategy for, 238–239
diagnostic tests in, 236–238
bone scanning, 238
computed tomography scanning, 237
electromyelography, 238
laboratory, 236
magnetic resonance imaging, 237–238
plain x-ray films, 237
differential diagnosis of, 232–235
employment screening in, 243
physical examination in, 236
rheumatologic conditions in, 234
spinal stenosis and, 235
structural conditions in, 234
systemic causes of, 234
therapy for, 239–243
activity restriction, 240
education, 243
exercise and physical treatments, 240–241
injection therapies, 241
medications, 241
spinal manipulation, 242–243
surgery, 241–242
vertebral disk herniation and, 235
Low density lipoprotein, relative coronary risk with, 952–953
Lower respiratory tract infections, aztreonam for, 740
carbapenems for, 753–754
Lugol’s solution, for thyroid storm, 177
Lung disease, restrictive, and chronic cough, 369
Lyme disease, cephalosporins for, 714
Lymphedema, classification of, 441
unilateral leg swelling in, 442–444
Lymphogranuloma venereum, in women, 1286
Macrolide antibiotics, adverse effects of, 540
alternatives to, 812, 940
in hepatic disease, pharmacokinetics of, 909
in vitro activities of, 806–807
indications for, 812
Macrovacular disease, in non-insulin-dependent diabetes mellitus, 292–293
Magnesium, for acute ischemic heart disease, 1016
Magnetic resonance imaging, for low back pain, 237–238
Malaria, clindamycin for, 854
Malignancy, and chronic fatigue, 318
and hypercalcemia, 82
and unilateral leg swelling, 445–446
psychosexual gynecology in, 1310–1311, 1314–1317
Malignant otitis externa, life-threatening, in diabetes mellitus, 55–60
Mastalgia, 1447–1448
Medical conditions, and bilateral massive adrenal hemorrhage, 110
Medical oophorectomy, for premenstrual syndrome, 1464
Medications, and chronic fatigue, 319
and euvoletic hyponatremia, 159–160
and involuntary weight loss, 304
Megestrol acetate, for involuntary weight loss, 311
Meningitis, antibiotic therapy for, in allergic patient, 937
bacterial, carbapenems for, 754
Streptococcus pneumoniae and, therapy of, 530–531
Menopause, 1337–1356
as coronary risk factor, 958
definition and endocrinology of, 1337–1338
hormone replacement therapy in, 1340–1341
mechanism of hormone action in, 1338–1340
psychosexual gynecology in, 1311, 1314
target tissue response to sex steroids in, 1338–1340
Menorrhagia, 331–337
- definition of, 1358
- differential diagnosis of, 333
- pharmacologic treatment of, 333
Menstrual cycle, normal, 1359–1360
Meropenem, antimicrobial spectrum of, 747
- dosing recommendations for, 750
- for infections in immunocompromised host, 568
- pharmacokinetics of, 748
Metabolic acidosis, in diabetic ketoacidosis, 13–15
Metabolic disorders, and involuntary weight loss, 303–304
- as coronary risk factors, 958–959
Methimazole, for thyroid storm, 176
Methotrexate, for ectopic pregnancy, 1330
Methysergide, for cluster headache prophylaxis, 276
- for migraine prophylaxis, 273
Metoclopramide, for migraine headache, 265, 269–271
Metoprolol, doses and actions of, 1072
- for perioperative myocardial ischemia, impact of, 1255
Metromenorrhagia, definition of, 1358
Metronidazole, 845–867
- absorption of, 856
- adverse effects of, 540, 858–860
- carcinogenicity concerns about, 860
- clinical use of, 860–863
- amebiasis, 863
- anaerobic infections, 860–861
- bacterial vaginosis, 863
- Clostridium difficile diarrhea, 861
- Crohn’s disease, 861
- giardiasis, 863
- Helicobacter pylori, 862
- perioperative, 863
- tetanus, 862
- trichomoniasis, 863
- distribution and tissue penetration of, 857
- dosage and route of administration of, 864
- in hepatic disease, pharmacokinetics of, 909
- interactions with alcohol, drugs, and laboratory tests, 859
- mechanisms of activity and resistance, 857
- metabolism and excretion of, 857
- mutagenicity concerns about, 860
- pharmacology of, 856–857
- spectrum of activity of, 858
- structure of, 846
- use in pregnancy and nursing mothers, 864

Metrorrhagia, definition of, 1358
Mezlocillin, concentration in lower respiratory system, 586
- in hepatic disease, pharmacokinetics of, 907
- indications, dosing, and preparations of, 685
- microbial susceptibility to, 681
- pharmacologic characteristics of, 683
Microbiologic activity, of antibiotics, 477
- and pharmacokinetics, 479
Migraine headache, criteria for, 262
- diagnosis of, 263–264
- treatment of, 264–274
- for infections in immunocompromised host, 568
- general, 264
- prophylactic, 271–274
- symptomatic, 264–268
Minimum inhibitory concentration, of antibiotics, 486–488
- and efficacy, 498
- for Streptococcus pneumoniae, 524
Minocycline, antibiotic sensitivities of, 791
- concentration in lower respiratory system, 586
Minoxidil, for impotence, 428, 430
Miomycin, in hepatic disease, pharmacokinetics of, 909
Misoprostol, for joint pain, 256–257
Mithramycin, for cancer-related hypercalcemia, comparative trials of, 88–89
Mitril valve, infective endocarditis of, complications with, 1226–1230
Molluscum contagiosum, genital, in women, 1289
Monobactams, adverse effects of, 540
Muscle enlargement, extraocular, with Graves’s ophthalmopathy, 199
Mycotic aneurysm, in infective endocarditis, echocardiography of, 1221
Myocardial infarction, echocardiography of, 1100
angiotensin-converting enzyme inhibitors for, early administration of, 1199–1200
- clinical characteristics predictive of, 1005
- complications with, 1226–1230
- death from, 1198
- diabetes and, 956
- hypertensive, 955–956
- in atherosclerosis regression trials, 987
- left ventricular remodeling following, 1193–1194
angiotensin-converting enzyme inhibitors for, 1194–1196
neurohormonal changes and, 1194
role of nitrates in, 1200
prognosis after, 1041
risk factors following, 962–963
Myocardial ischemia, anti-ischemic drug therapy for, 1067–1068, 1255
antianginal therapy for, 1076
pathophysiology of, 1064–1066
signs of, 1065
Myocardial necrosis, serum markers of, 1008–1009
Myocardial oxygen demand, increased, in coronary artery disease, 1065
Myocardial perfusion scintigraphy, diagnostic/prognostic value of, 1032–1033
Myxedema coma, 185–194
diagnosis of, 188–189
clinical presentation, 188
laboratory testing, 188–189
pathogenesis of, 185–188
precipitating factors in, treatment of, 191–192
treatment of, 189–192
course of therapy, 192
hypoglycemia treatment, 191
hyponatremia treatment, 191
hypotension treatment, 191
hypothermia treatment, 190
respiratory support, 190–191
steroid administration, 190
thyroid hormone replacement, 189–190
Nadolol, doses and actions of, 1072
Nafcillin, in hepatic disease, pharmacokinetics of, 907
Nalidixic acid, 869–894. See also Quinolones.
Naproxen sodium, for migraine headache, 265
for migraine prophylaxis, 272
for tension headache, 278
Narcolepsy, and excessive sleepiness, 406–407
Necrotizing soft tissue infections, life-threatening, in diabetes mellitus, 59, 70–73
Neisseria gonorrhoeae, cervicitis with, 1277
infections with, treatment regimens for, 1280
Neomycin-erythromycin, for antibiotic prophylaxis, in colon resection, 518
Nephropathy, in non-insulin-dependent diabetes mellitus, 294–296
Nephrotoxicity, with aminoglycosides, 775–776
Netilmicin, chemical configuration of, 765
in hepatic disease, pharmacokinetics of, 904
in renal failure, dosing of, 921
Neurogenic claudication, and low back pain, 235
Neurohormonal changes, in postinfarction left ventricular remodeling, 1194
Neurologic adverse effects, of metronidazole, 858–859
Neurologic disease, and impotence, 422
Neurologic manifestations, in nonketotic hypertonicity, 44–45
Neuropathy, in non-insulin-dependent diabetes mellitus, 296–297
Neuropsychiatric manifestations, in bilateral massive adrenal hemorrhage, 114–115
Neutropenia, febrile, antibiotic therapy for, in allergic patient, 937
carbapenems for, 754
in immunocompromised host, 559–560
quinolones for, 883–884
Nifedipine, cardiovascular actions of, 1075
for coronary artery disease with concomitant medical conditions, 1077
for heart failure, studies of, 1177
for migraine prophylaxis, 272
Nipple discharge, 1448–1450
Nitrates, for acute ischemic heart disease, 1014–1015
for angina pectoris, 1068–1069
general actions of, 1068
role in postinfarction left ventricular remodeling, 1200
tolerance to, 1069–1071
Nitroglycerin, for impotence, 428
for perioperative myocardial ischemia, impact of, 1255
Nonketotic hypertonicity, in diabetes mellitus, 39–52
causes of, 41, 43
clinical presentation of, 44–46
history, 44
laboratory findings, 45–46
neurologic manifestations, 44–45
physical examination, 44
epidemiology of, 42–44
mortality and morbidity in, 46–47
nonketoacidosis in, reason for, 42
prevention of, 49–50
reason for, 39–41
treatment of, 47–49
electrolyte replacement, 48
goals of therapy, 47–48

Nadolol, doses and actions of, 1072
Nafcillin, in hepatic disease, pharmacokinetics of, 907
Nalidixic acid, 869–894. See also Quinolones.
Naproxen sodium, for migraine headache, 265
for migraine prophylaxis, 272
for tension headache, 278
Narcolepsy, and excessive sleepiness, 406–407
Necrotizing soft tissue infections, life-threatening, in diabetes mellitus, 59, 70–73
Neisseria gonorrhoeae, cervicitis with, 1277
infections with, treatment regimens for, 1280
Neomycin-erythromycin, for antibiotic prophylaxis, in colon resection, 518
Nephropathy, in non-insulin-dependent diabetes mellitus, 294–296
Nephrotoxicity, with aminoglycosides, 775–776
Netilmicin, chemical configuration of, 765
in hepatic disease, pharmacokinetics of, 904
in renal failure, dosing of, 921
Neurogenic claudication, and low back pain, 235
Neurohormonal changes, in postinfarction left ventricular remodeling, 1194
Neurologic adverse effects, of metronidazole, 858–859
Neurologic disease, and impotence, 422
Neurologic manifestations, in nonketotic hypertonicity, 44–45
Neuropathy, in non-insulin-dependent diabetes mellitus, 296–297
Neuropsychiatric manifestations, in bilateral massive adrenal hemorrhage, 114–115
Neutropenia, febrile, antibiotic therapy for, in allergic patient, 937
carbapenems for, 754
in immunocompromised host, 559–560
quinolones for, 883–884
Nifedipine, cardiovascular actions of, 1075
for coronary artery disease with concomitant medical conditions, 1077
for heart failure, studies of, 1177
for migraine prophylaxis, 272
Nipple discharge, 1448–1450
Nitrates, for acute ischemic heart disease, 1014–1015
for angina pectoris, 1068–1069
general actions of, 1068
role in postinfarction left ventricular remodeling, 1200
tolerance to, 1069–1071
Nitroglycerin, for impotence, 428
for perioperative myocardial ischemia, impact of, 1255
Nonketotic hypertonicity, in diabetes mellitus, 39–52
causes of, 41, 43
clinical presentation of, 44–46
history, 44
laboratory findings, 45–46
neurologic manifestations, 44–45
physical examination, 44
epidemiology of, 42–44
mortality and morbidity in, 46–47
nonketoacidosis in, reason for, 42
prevention of, 49–50
reason for, 39–41
treatment of, 47–49
electrolyte replacement, 48
goals of therapy, 47–48
Nonketotic hypertonicity (Continued)
insulin and other medications, 48–49
monitoring of, 49
water restriction and, 43–44
Nonsteroidal anti-inflammatory drugs, for abnormal uterine bleeding, 1371
for chronic fatigue syndrome, 324
for heart failure, 1183
for joint pain, 256
for menorrhagia, 333–334
for migraine headache, 264
Norepinephrine, in critical illness, 213–214
Norfloxacin, pharmacokinetics of, 873
in hepatic disease, 908
spectrum of in vitro activity of, 872
Nursing mothers, clindamycin use in, 855
metronidazole use in, 864

Obese patients, aminoglycosides for, dosing weight correction factor for, 774
Obesity, and dysfunctional uterine bleeding, 339
Obstetric conditions, and bilateral massive adrenal hemorrhage, 110
Obstetric/gynecologic infections, carbapenems for, 753
Obstructive sleep apnea syndrome, and excessive sleepiness, 404–406
diagnosis of, objective standards for, 411
parameters for, 408
Ocular pain, with Graves’s ophthalmopathy, 197
Odontogenic infections, clindamycin for, 851–852
Ofloxacin. See also Quinolones.
concentration in lower respiratory system, 587
concentration ratios for, 499
for community-acquired pneumonia, 470
parenteral vs oral, comparative clinical trials of, 501
pharmacokinetics of, 873
in hepatic disease, 908
spectrum of in vitro activity of, 872
Oligomenorrhea, definition of, 1358
Ophthalmologic manifestations, in infective endocarditis, 1219
Ophthalmopathy, Graves’s, 195–209. See also Graves’s ophthalmopathy.
Optic disc edema, with Graves’s ophthalmopathy, 202
Optic neuropathy, with Graves’s ophthalmopathy, 200
Oral contraceptives, 1381–1386
and uterine bleeding, 1365
composition and formulation of, 1381–1382
for abnormal uterine bleeding, 1370–1371
for menorrhagia, 333
for premenstrual syndrome, 1464
health benefits of, 1382–1384
health risks of, 1385–1386
cancer, 1385–1386
cardiovascular disease, 1385
in women over 35, 1386
mechanism of action of, 1382
side effects of, 1384
use of, psychosexual gynecology in, 1313
Oral disorders, and involuntary weight loss, 305
Orbital decompression, for decreasing vision, in Graves’s ophthalmopathy, 205
Orbital irradiation, for decreasing vision, in Graves’s ophthalmopathy, 205
Orthopedic manifestations, in infective endocarditis, 1219
Orthostatic hypotension, management of, 1167–1168
Osmolarity, total vs effective, determination of, 40
Osmotic demyelination syndrome, 164
Osteomyelitis, clindamycin for, 853
parenteral vs oral antibiotics for, 502
Osteoporosis, prevention of, with hormone replacement therapy, 1340
Otitis externa, malignant, life-threatening, in diabetes mellitus, 55–60
Otoxicity, with aminoglycosides, 776–777
Ovulation, basal body temperature determination of, 332
Ovulatory status, determination of, 330–331
Oxidation, as coronary risk factor, 958
Oximetry readings, in sleep assessment, 409
Oxygen, for cluster headache, 275

Pacemaker, for sustained ventricular tachycardia, 1108
Pain, in bilateral massive adrenal hemorrhage, 113–114
Pain relief, for acute ischemic heart disease, 1016
Palpitations, 449–456
causes of, 449–450
characterization of, 450
diagnostic studies in, 453–455
history in, 450–452
initiation of, 452
physical examination in, 452–453
treatment of, 455
types of, 451

Pamidronate, for cancer-related
hypercalcemia, comparative trials of, 88–89
for hypercalcemic crisis, 86

Papanicolaou smear, abnormal, 345–360,
1427–1441
management of, 350–357, 1435–1440
atrophic changes, 1439
glandular neoplasia, 1439–1440
malignancies, 1440
reactive changes, 1438–1439
abnormal cytology in
immunosuppressed woman, 356–357
alternatives to, 1433
classification of, 349–350, 1429–1431
glandular cell abnormalities on, 357
infectious agents in, 352–353
normal, 351–352
of human papillomavirus, 1431–1433
reactive changes in, 353
squamous cell abnormalities on,
353–356
strengths and weaknesses of, 1427–1429
unsatisfactory sample in, 352

Papillomavirus, genital, in women,
1287–1289
human, and cervical cancer risk, 346

Para-aminosaliclyc acid, in hepatic
disease, pharmacokinetics of, 910

Parathyroid hormone, deficiency of, and
hypocalcemia, 97–98
hypersecretion of, and hypercalcemia, 80
resistance of, and hypocalcemia, 98–99

Parkinson’s disease, and involuntary
weight loss, 306

Partner abuse, psychosexual effects of,
1309–1310

Patient compliance, with antimicrobials,
539–541

Patient education, in chronic fatigue
syndrome, 324

Pediculosis pubis, in women, 1289

Pefloxacin, in hepatic disease,
pharmacokinetics of, 908

Pelvic inflammatory disease,
cephalosporins for, 714
intrauterine devices and, 1393–1394
outpatient treatment regimens for, 1281
with cervicitis, 1278
Pelvic malignancy, psychosexual
gynecology in, 1314–1317

Pelvic mass, female, 1481–1493
diagnostic imaging studies of,
1488–1491
computed tomography, 1490–1491
cost of, 1489
magnetic resonance imaging, 1491
ultrasonography, 1488–1490
history of, 1487–1488
laboratory tests for, 1491–1492
management of, 1492–1493
patient age in, 1482–1486
adolescence, 1483–1484
childhood, 1482–1483
perimenopausal and
postmenopausal, 1486
reproductive years, 1484–1486
physical examination of, 1488
leiomyomata, 1485

Pelvic organ prolapse, 1473–1479
diagnosis of, 1474–1476
diagnostic tests for, 1476–1477
treatment options for, 1477–1478

Pelvic pain, chronic, 1411–1425
cyclic and noncyclic causes of, 1412
evaluation of patient with, 1411–1413
gastrointestinal causes of, 1413–1414
musculoskeletal causes of, 1416–1418
psychiatric factors in, 1418–1420
sexual abuse history, 1420
somatization disorder, 1418–1420
role of antidepressants in, 1420
role of surgical management in,
1421–1424
adhesiolysis, 1422
diagnostic laparoscopy, 1421–1422
hysterectomy, 1423–1424
presacral neuroectomy, 1423
uterine suspension, 1422–1423
uterosacral nerve ablation, 1423
urinary tract causes of, 1414–1416
interstitial cystitis, 1416
urethral syndrome, 1415–1416

Penicillin(s), adverse effects of, 540
allergy to, alternatives for, 938
antipseudomonal, 679–693
adverse effects of, 686–687
antimicrobial spectrum of, 680–682
clinical pharmacokinetics of, 683–684
clinical use of, 687–690
drug interactions with, 687
empiric therapy with, 689–690
Penicillin(s) (Continued)
indcations, dosing, and preparations of, 684–686
pharmacologic characteristics of, 683
prophylaxis with, 689
safety profile of, 686–687
synergism and antagonism of, 682–683
concentration in lower respiratory system, 586
for *Streptococcus pneumoniae*, susceptibility of, 524–525
for *Treponema pallidum* infection, 1285
resistance to, of *Streptococcus pneumoniae*, 525–527
mechanism of, 529
semi-synthetic, development of, 696
Penile prostheses, for impotence, 427
Penile self-injection therapy, for impotence, 426–427
Penis, nocturnal tumescence of, 417–418
vascular system of, 416
Pentoxifylline, for vasculogenic impotence, 424
Perforation, in infective endocarditis, echocardiography of, 1221
Perfusion, end points of, characteristics of, 1028
Perfusion imaging, with pharmacologic stress testing, for preoperative coronary risk assessment, 1250–1251
prognostic value of, 1042
Perfusion scintigraphy, clinical applications of, 1030–1033
diagnostic accuracy of, 1031
imperfections in, 1033–1034
method of, 1028–1030
sensitivity of, degree of coronary involvement and, 1030
Pericarditis, myocardial infarction vs, 1006
Perimenopause, issues in, 1343–1344
Periodic abstinence, for contraception, 1396–1397
Peritoneal cavity, normal defense mechanisms of, 600–601
Peritoneal dialysis, for thyroid storm, 178
Peritonitis, natural history of, 599–602
Pesaries, for pelvic prolapse, 1478
Pharmacodynamics, of antibiotics, 484–490
application in clinical practice, 490–493
concentration-dependent killing, 488–489
concentration-independent killing, 489–490
concentration vs time, 485
Pharmacokinetics, of antibiotics, 478–484
analysis of, 484
clearance, 480–481
continuous infusions, 483–484
elimination rate constant, 482
half-life, 482–483
protein binding, 479–480
volume of distribution, 481
Pharmacologic interventions, for supraventricular tachyarrhythmias, 1123–1124
Pharmacologic stress testing, for preoperative coronary risk assessment, 1250–1252
Phenelzine, for migraine prophylaxis, 273
Phentolamine mesylate, for pheochromocytoma, 145
Pheochromocytoma, 131–153
biochemical/pharmacologic testing of, 135–139
chromogranin A, 139
clonidine suppression test, 137–138
drugs affecting, 135–137
provocative, 138–139
screening, 135–137
bladder, 146
clinical presentation of, 133–135
complications of, 133–134
CT scan of, 140
differential diagnosis of, 135
localization of, 139–142
magnetic resonance imaging scan of, 141
malignant, 145–146
management of, 142–146
medical, 143–145
surgery, 142–143
pathophysiology of, 131–133
pregnancy and, 146
presenting signs and symptoms of, 134
Phosphate, for cancer-related hypercalcemia, comparative trials of, 89–90
for diabetic ketoacidosis, 21
Phosphodiesterase inhibitors, for heart failure, studies of, 1177
Physical treatments, for low back pain, 240–241
Physician-patient relationship, in irritable bowel syndrome management, 382
Pindolol, doses and actions of, 1072
Piperacillin, doses and actions of, 1072
Piperacillin, concentration in lower respiratory system, 586
for infections in immunocompromised host, 567
indications, dosing, and preparations of, 685–686
microbial susceptibility to, 681
pharmacologic characteristics of, 683
with tazobactam, in vitro activity and cost of, 698
indications for, 702
Plaque, in ischemic heart disease, 1002
Plasma exchange, for thyroid storm, 178
Plasmapheresis, for thyroid storm, 182
Pneumocystis carinii infections, clindamycin for, 854
Pneumonia(s), antibiotic treatment of,
581–597
pharmacokinetic and host factors in, 584
selection of, factors in, 582–583
tissue penetration in, 583–584
cephalosporins for, 713–714
community-acquired, antibiotics for, 470
atyypical, treatment of, 589–590
bacterial, 584–588
in allergic patient, antibiotic therapy for, 937
in normal host, empiric therapy for, 590
parenteral vs oral antibiotics for, 503–504
pathogens and therapy of, 588
in elderly, treatment of, 654–655
nosocomial, atypical, 592–593
bacterial, 590–592
in normal host, empiric therapy of, 593
therapy for, empiric vs specific, 593
intravenous vs oral, 593–594
Pneumothorax, myocardial infarction vs, 1006
Polycystic ovary syndrome, and
dysfunctional uterine bleeding, 338–339, 1361
Polymenorrhea, definition of, 1358
Polysomnography, in sleep assessment, 409
indications for, 410
Popliteal cyst, unilateral leg swelling in, 439
Positron emission tomography, stress
echocardiography vs, 1048
Postcoital contraception, 1380–1381
Postnasal drip, and chronic cough, 363–365
Potassium, depletion of, in diabetic
eketoacidosis, 14–15
for diabetic ketoacidosis, 19–20
Potassium iodide, for thyroid storm, 177
Prednisone, for cluster headache
prophylaxis, 276
for decreasing vision, in Graves's opthalmopathy, 205
Pregnancy, accidental, with contraceptive use, 1378
and pheochromocytoma, 146
clindamycin use in, 855
complications of, early, diagnosis of,
1319–1335
eye, diagnosis of, 1319–1335
ectopic, 1325–1327
management of, 1329–1331
first-trimester, disorders in, 1323–1327
complete abortion, 1324
management of, 1329
ectopic pregnancy, 1325–1327
management of, 1329–1331
hemorrhagic corpus luteum, 1324–1325
inevitable/incomplete abortion, 1323–1324
management of, 1328
management of, 1327–1331
missed abortion, 1324
management of, 1329
threatened abortion, 1323
management of, 1327–1328
drug use in, 1332–1334
normal, 1319–1323
hormone levels in, 1320
signs and symptoms of, 1320
sonography of, 1320–1322
metronidazole use in, 864
psychosexual effects of, 1306–1308
uncomplicated pyelonephritis in, 640
Premenstrual syndrome, 1457–1472
as socially constructed label, 1457–1458
cause of, 1461–1462
criteria for, 1459
diagnosis of, 1459–1460
differential diagnosis of, 1460–1461
association with depression, 1460
gynecologic conditions, 1461
medical conditions, 1460–1461
in perimenopause, 1344
prevalence of, 1458–1459
symptoms of, 1458
treatment of, 1462–1469
anxiolytics, 1465
atenolol, 1466–1467
behavioral modification, 1469
bromocriptine, 1465
caffeine restriction, 1467–1468
diet, 1467
diuretics, 1466
exercise, 1468
medical oophorectomy, 1464
medications, 1463
oral contraceptives, 1464
Premenstrual syndrome (Continued)
progesterone, 1464–1465
prostaglandin-related, 1467
salt restriction, 1467
selective serotonin reuptake inhibitors, 1466
surgery, 1463
thyroid hormone, 1465
tricyclic antidepressants, 1465–1466
vitamin B₆, 1468
vitamin E, 1468
Presacral neurectomy, for chronic pelvic pain, 1423
Procainamide, for atrial fibrillation, 1141–1142
Progesterone, for abnormal uterine bleeding, 1370
for premenstrual syndrome, 1464–1465
Prokinetic agents, for irritable bowel syndrome, 385
Prolactinoma, and impotence, 420
treatment of, 423
Propafenone, for atrial fibrillation, 1141, 1143
Propranolol, doses and actions of, 1072
for migraine prophylaxis, 272
Propylthiouracil, for thyroid storm, 176
Prostatic infection, empiric antibiotic therapy for, 556
Prostatectomy, antibiotic prophylaxis for, 513
Prostatitis, bacterial, quinolones for, 875–876
Prosthetic valves, infective endocarditis in, 1211–1213
Protein, binding of, by antibiotics, 479–480
enhanced, and hypocalcemia, 95–96
metabolism of, in diabetic ketoacidosis, 13
Proteus mirabilis, antibiotic susceptibility of, 681
Protozoa, clindamycin spectrum of activity against, 848
metronidazole spectrum of activity against, 858
Pseudoclaudication, and low back pain, 235
Pseudohyponatremia, approach to, 156–157
Pseudohypoparathyroidism, and hypocalcemia, 98
Pseudomonas, antibiotic susceptibility of, 681
antibiotics for, minimum inhibitory concentrations of, 682
penicillins for, 679–693
Pseudomonas aeruginosa, and intra-abdominal sepsis, 602–603
and nosocomial pneumonia, 592
in immunocompromised host, 562
Pseudosepsis, definition of, 551, 553
Psychiatric disorders, and chronic fatigue syndrome, 323
and insomnia, 397–398
Psychiatric medications, and impotence, 418–419
Psychiatric testing, for syncope evaluation, 1163
Psychological problems, with sexual difficulties, in women, 1300
Psychosexual gynecology, 1299–1317
anorgasmia, 1303–1304
common disorders, 1310–1311
disorders of sexual desire, 1304–1305
dyspareunia, 1301–1302
hormonal concerns, 1312–1314
infection, 1311
infertility, 1311–1312
malignancy, 1310–1311, 1314–1316
menopause, 1311
partner abuse, 1309–1310
pregnancy, 1306–1308
sexual victimization, 1308–1309
sexuality, 1301
sexually transmitted diseases, 1305–1306
vasinismus, 1302–1303
women with cancer, 1314–1316
Psychotherapy, for irritable bowel syndrome, 385
Pulmonary embolus, myocardial infarction vs, 1006
Pulmonary infections, cephalosporins for, 713–714
clindamycin for, 852
Pulmonary manifestations, in infective endocarditis, 1218
Pulmonary tumors, and chronic cough, 369
Pyelonephritis, empysematous, life-threatening, in diabetes mellitus, 59, 67–70
in adults, 619–649
and altered intrarenal antibiotic pharmacokinetics, 638
and altered renal antibiotic concentrations, 631
clinical syndromes of, 621–622
complicated, 622, 641–642
controlling inflammatory response in, 645–646
diagnosis of, 623–625
follow-up of, 644–645
pathogenesis of, 627–628
pathogens responsible for, 625–627
treatment of, antibiotic efficacy in, 633
antibiotic levels in, 630–634
choice of therapy for, 634–635
empiric, 620–621
failure of, 630
future approach to, 645–646
guidelines for, 620–621
high failure rate of, 621
immediate, 634–636
principles of, 629–630
recommedations and costs of, 637
sequential, 633–634
uncomplicated, 621–622, 635–641
in men, 640–641
in women, 635–640
acute moderate, 638–639
acute severe with possible septicemia, 639
in pregnancy, 640
recurrent, 639–640
subclinical, 635–637
with obstruction, 642–643
with structural or functional abnormalities, 642–643
with underlying disease, 643–644
cystic renal disease, 644
diabetes, 643–644
immunosuppression, 644
with urologic manipulation, 643
parenteral vs oral antibiotics for, 503

Quinidine, for atrial fibrillation, 1140–1142
Quinolones, 869–894
adverse effects of, 540, 886–887
clinical uses of, 874–886
bacterial prostatitis, 875–876
bone/joint infections, 880–881
gastrointestinal infections, 876–878
neutropenia, 883–884
prophylactic, 883–884
respiratory tract infections, 878–880
sexually transmitted diseases, 876
skin infections, 881–883
urinary tract infections, 874–875
drug interactions with, 887–888
for infections in immunocompromised host, 568–570
for transitional therapy, 470
intrarenal concentrations of, 632
parenteral vs oral, comparative clinical trials of, 501
pharmacokinetics of, 871–874
in hepatic disease, 907
spectrum of in vitro activity of, 871–872
structure and mechanisms of action of, 870–871

Radiation exposure, in stress echocardiography, 1049–1050
Ramipril, for heart failure, studies of, 1177
Recreational drugs, and impotence, 419
Reflex sympathetic dystrophy, causes of, 444
unilateral leg swelling in, 444–445
Rehydration, for diabetic ketoacidosis, 18
Renal clearance, of antibiotics, 480–481
Renal disease, and involuntary weight loss, 305
cystic, pyelonephritis with, 644
Renal failure, antibiotic dosing in, 919–933
Renal fluid losses, and volume-contracted hyponatremia, 158–159
Renal manifestations, in infective endocarditis, 1219
Renal transplantation, pyelonephritis with, 643
Renin-angiotensin-aldosterone axis, regulation of, in critical illness, 216–217
Reperfusion therapy, for acute ischemic heart disease, 1010–1011
Reproductive axis, in critical illness, 220
Respiratory disorders, and excessive sleepiness, 404–406
and involuntary weight loss, 305
Respiratory function, in myxedema coma, 185–186
Respiratory support, for myxedema coma, 190–191
Respiratory tract infections, quinolones for, 878–880
tetracyclines for, 798
Restless leg syndrome, and insomnina, 399
Retinopathy, in non-insulin-dependent diabetes mellitus, 293–294
Rheumatoid factor, in joint pain, 252
Rhinocerebral mucormycosis, life-threatening, in diabetes mellitus, 59–64
Rhythm strip, for arrhythmia detection, in syncope evaluation, 1158
Rifampin, in hepatic disease, 914
pharmacokinetics of, 910
Ring abscess, in infective endocarditis, echocardiography of, 1221–1224
Roxithromycin, in hepatic disease, pharmacokinetics of, 909

Salt restriction, for premenstrual syndrome, 1467
Sarcoidosis, and uterine bleeding, 1363
Scabies, genital, in women, 1289–1290
Sciatica, surgical referral in, indications for, 242
with low back pain, 233
Scintigraphy, perfusion, 1028–1034. See also Perfusion scintigraphy.

Sepsis, antibiotic therapy for, in allergic patient, 937
antibiotic treatment of, 551–558
choice of, 553
clinical approach to, 552–554
conditions associated with, 554
conditions mimicking, 553
double-drug therapy for, indications for, 555
intra-abdominal, 599–617. See also Intra-abdominal sepsis.
organ system involvement in, 554
antibiotic selection for, 554–557
Septicemia, definition of, 551
with acute severe pyelonephritis, 639
Serotonin, and premenstrual syndrome, 1462
Serotonin reuptake inhibitors, selective, for premenstrual syndrome, 1466
Serratia marcescens, antibiotic susceptibility of, 681
Sexual abuse history, and chronic pelvic pain, 1420
Sexual difficulties, causes of, 1300
incidence of, 1299
psychosexual nature of, 1304–1305
Sexual history, goals of, 1299
Sexual victimization, psychosexual effects of, 1308–1309
Sexuality, in women, 1301
Sexually transmitted diseases, psychosexual effects of, 1305–1306
quinolones for, 876
tetracyclines for, 798
Shock, septic, signs of, 552
Skin infections, cephalosporins for, 713
cloxacillin for, 852
parenteral vs oral antibiotics for, 502
quinolones for, 881–883
Sleep, insufficient, syndrome of, 403–407
normal, 392–394
effects of age on, 394–395
Sleep apnea syndrome, and excessive sleepiness, 404–406
diagnosis of, objective standards for, 411
parameters for, 408
Sleep disorder(s), 391–414
and chronic fatigue, 319
as coronary risk factor, 960
background of, 392
cardinal manifestations of, 394–396
circadian rhythm disturbances and, 398–399
common diagnoses in, 396
monitoring of, indications and standards, 407–411
Sleepiness, excessive, 402–407
causes of, 407
daytime tests of, 409
insufficient sleep syndrome and, 403–404
narcolepsy and, 406–407
obstructive sleep apnea syndrome and, 404–406
Small intestine, resection of, antibiotic prophylaxis for, 512, 518–519
Smoking, as coronary risk factor, 959
Snoring, disruptive, and obstructive sleep apnea syndrome, 405
Sociopathy, and involuntary weight loss, 308
Sodium, normal metabolism of, 155–156
regulation of, in myxedema coma, 186
Sodium valproate, for migraine prophylaxis, 273
Soft tissue infections, cephalosporins for, 713
cloxacillin for, 852
necrotizing, life-threatening, in diabetes mellitus, 59, 70–73
parenteral vs oral antibiotics for, 502
quinolones for, 881–883
Solute gain, and nonketotic hypertonicity, 41
Somatization disorder, and chronic pelvic pain, 1418–1420
Somatotropin, in critical illness, 1141, 1143–1144
Sotalol, for atrial fibrillation, 1141, 1143–1144
Spermicides, for contraception, 1392
Spinal manipulation, for low back pain, 242–243
Spinal stenosis, and low back pain, 235
Spine, anatomy of, in low back pain, 232
Spondylitis, and low back pain, 234
Squamous cell abnormalities, on Papanicolaou smear, management in, 353–356, 1436–1437
Squamous intraepithelial lesions, cervical, management of, 1434–1435
high-grade, 1434–1435
low-grade, 1435–1436
ST-segment elevation, in myocardial infarction, 1005, 1007
Staphylococcus species, and infective endocarditis, 1211
in immunocompromised host, 562
Sterilization, surgical, 1379–1380
Steroids, for joint pain, 257
for myxedema coma, 190
Streptococci, and infective endocarditis, 1211
Streptococcus pneumoniae, antibiotic-resistant, 523–535
  mechanism of spread of, 528
  risk factors for acquisition of, 528–529
  cefotaxime-resistant, 527
  erythromycin-resistant, 527
  infection with, treatment of, 530
  multiple antibiotic resistance of, 527–528
  penicillin-resistant, 525–527
  susceptibility testing of, 524–525
  vaccine against, 531–532
Streptococcus viridans, in immunocompromised host, 562
Streptokinase, for acute ischemic heart disease, 1013
Streptomycin, dosing of, in renal failure, 921
Stress, and irritable bowel syndrome, 378
Stress echocardiography, debate concerning, 1052
  disadvantages of, 1049–1051
  cost effectiveness, 1050–1051
  potential for abuse, 1051
  radiation exposure, 1049–1050
  dynamic, 1041–1043
  dynamic exercise, 1039–1041
  method of, 1049–1051
  acceptance and integration of, 1052–1054
  choice of, 1054
  development of, 1034
  pharmacologic, agents for, 1043–1045
  results of, 1036
  settings for use of, 1047–1049
  dyspnea, 1047
  left bundle branch block, 1049
  low pretest likelihood, 1048–1049
  women, 1047–1048
  stress perfusion scintigraphy vs, 1034–1037
  views in, 1035
Stress hormones, in critical illness, 211–215
Stress imaging, 1025–1061
  function vs perfusion in, 1037–1038
  in coronary artery disease, current status of, 1026–1027
  direct vs indirect, 1026
  ischemic end points in, 1027–1028
  methods of, 1027
  objectives of, 1025
  reasons for, 1025–1026
  in exercise, echocardiography vs perfusion scintigraphy, 1038
Stress testing, exercise, for preoperative coronary risk assessment, 1249–1250
  pharmacologic, for preoperative left ventricular function assessment, 1252
Stress urinary incontinence, 1473–1479. See also Urinary incontinence.
Stroke, and involuntary weight loss, 306
Substance abuse, and chronic fatigue, 319
Suction curette, for endometrial biopsy, 1368
Sulbactam, concentration in lower respiratory system, 586
Sulfa drugs, allergy to, alternatives for, 941
Sumatriptan, for cluster headache, 275
  for migraine headache, 267–269
Supraventricular tachyarrhythmias, 1121–1134
  antiarrhythmic interventions for, 1123–1130
  catheter ablation, 1125–1128
  costs and benefits of, 1129–1130
  optimization of, 1130
  patient selection for, 1128–1129
  devices, 1125
  nonpharmacologic, 1124–1130
  outcomes in, 1128
  pharmacologic, 1123–1124
  surgical, 1125
  future directions in, 1130
  mechanisms of, 1122–1123
  pathophysiology of, 1121–1122
Surgery, clean, antibiotic prophylaxis for, 512, 514–515
  for low back pain, 241–242
  noncardiac, coronary risk assessment for, 1241–1262
Surgical conditions, and bilateral massive adrenal hemorrhage, 110
Susceptibility, and antibiotic failure, 664–665
Sweat fluid losses, and volume-contracted hyponatremia, 158
Syncope, 1153–1170
  causes of, 1154–1155
  diagnostic evaluation of, 1155–1164
    algorithm for, 1165
    approach to, 1164–1166
    arrhythmia detection, 1158–1162
    carotid massage, 1158–1159
    electrocardiogram/rhythm strip, 1158
    electrophysiologic studies, 1159, 1161–1162
    prolonged electrophysiologic monitoring, 1159–1160
    diagnostic testing, 1156, 1158
    history, 1155–1156
    low yield tests in, 1164
    physical examination, 1156
    psychiatric testing, 1163
    upright tilt testing, 1162–1163
    drugs causing, 1156
Syncope (Continued)
management of, 1166–1168
orthostatic hypotension and, 1167–1168
pathophysiology of, 1153–1154
prognosis in, 1164
Syndrome of inappropriate antidiuretic hormone secretion, 161–162
Synovial fluid, analysis of, for joint pain, 250
Syphilis, genital ulcers with, in women, 1283–1286

Tachyarrhythmias, supraventricular, 1121–1134. See also Supraventricular tachyarrhythmias.
Tachycardia, in myocardial infarction, 1007
Teicoplanin, 833–844
adverse effects of, 839
antibacterial activity of, vancomycin vs, 835
antimicrobial spectrum of, 833–836
clinical pharmacokinetics of, 836–839
clinical use of, 840–841
dosage recommendations for, 837–838
safety profile of, 839–840
structure of, 834
Temporal arteritis, and headache, 280
Temporomandibular disorders, and headache, 281
Tension headache, 277–279
criteria for, 277
treatment of, 278–279
Testosterone deficiency, and impotence, 420
treatment of, 423
Tetanus, metronidazole for, 862
Tetany, in severe hypocalcemia, 94–95
Tetracycline(s), 789–801
adverse effects of, 540
adverse reactions to, 795–796
allergy to, alternatives for, 940
antibiotic sensitivities of, 791
antimicrobial spectrum of, 790–791
clinical pharmacokinetics of, 792–794
clinical use of, 797–798
concentration in lower respiratory system, 586
dosing recommendations for, 794
drug interactions with, 796–797
prophylaxis with, 798
resistance patterns of, 791–792
structures of, 790
Treatment with, 798–799
Thromboembolic diathesis, and bilateral massive adrenal hemorrhage, 111
Thrombolytic therapy, for acute ischemic heart disease, 1010–1011
Thrombotic diathesis, and bilateral massive adrenal hemorrhage, 113
Thyroid, changes in, in critical illness, 217–219
disorders of, and uterine bleeding, 1362–1363
function of, in joint pain, 253–254
Thyroid hormone, for premenstrual syndrome, 1465
physiology of, 169–171
replacement of, for myxedema coma, 189–190
Thyroid storm, 169–184
clinical presentation of, 173–174
diagnosis of, 174–175
pathogenesis of, 171–172
pathophysiology of, 169–172
precipitating event in, 174
treatment of, 179
prevention of, 180
treatment of, 175–180
guidelines for, 176
response to, 180
Thyroxine, abnormal level of, in critical illness, 219
Ticarcillin, concentration in lower respiratory system, 586
indications, dosing, and preparations of, 684–685
microbial susceptibility to, 681
pharmacologic characteristics of, 683
with clavulanic acid, in vitro activity and cost of, 698
indications for, 702
Tilt table testing, for syncope evaluation, 1162–1163
Timolol, doses and actions of, 1072
Tobramycin, chemical configuration of, 764
concentration in lower respiratory system, 586
dosing of, in renal failure, 921
for infections in immunocompromised host, 567
Toxoplasma infections, clindamycin for, 854
Transesophageal echocardiography, role in embolization prevention in atrial fibrillation, 1146–1147
Transitional therapy, antibiotic, 469–471
Treponema pallidum, and genital ulcers, in women, 1283
treatment regimens for, 1285
Trichomonas infection, metronidazole for, 863
on Papanicolaou smear, management in, 352
vaginal, 1276–1277
Tricyclic antidepressants, for irritable bowel syndrome, 384
  for premenstrual syndrome, 1465–1466
  for tension headache, 278
Triglycerides, relative coronary risk with, 953
Triiodothyronine, low, in critical illness, 218–219
  mechanism of action of, 171
Trimethoprim-sulfamethoxazole, allergy to, alternatives for, 941
  concentration in lower respiratory system, 587
  for infection in immunocompromised host, 576
Trousseau’s sign, in severe hypocalcemia, 94–95
Twitching, in severe hypocalcemia, 94–95

Ultrasonography, of intra-abdominal sepsis, 604
Upper respiratory tract infections, clindamycin for, 851
Upright tilt testing, for syncope evaluation, 1162–1163
Ureidopenicillins, antipseudomonal, antimicrobial spectrum of, 680–682
Urethral syndrome, and chronic pelvic pain, 1415–1416
Uric acid, in joint pain, 254
Urinary catheterization, pyelonephritis with, 643
Urinary incontinence, stress, 1473–1479
  differential diagnosis of, 1475
  epidemiology of, 1473–1474
  treatment outcomes in, 1478
Urinary tract, lower, function of, medications affecting, 1476
Urinary tract infection(s), aztreonam for, 740
  bacteria responsible for, 626
  in elderly, 655–657
  parenteral vs oral antibiotics for, 503–504
  quinolones for, 874–875
  treatment of, 619–649. See also Pyelonephritis.
Urinary tract obstruction, pyelonephritis with, 642–643
Urologic manipulation, pyelonephritis with, 643
Uropathogens, antibiotic susceptibility of, 626–627
Uterine bleeding, abnormal, 329–344, 1357–1376
  anovulatory, 335–337
  differential diagnosis of, 336
  evaluation of, 337
  approach to, 330
  diagnosis of, 1365–1370
  endometrial sampling, 1366
  hormone measurements, 1366
  medical management of, 1369–1371
  patterns of, 330
  and reproductive tract disease, 1363–1365
  and systemic disease, 1362–1363
  anovulatory, 1360–1362
  blood loss in, 1361
  definition of, 1358
  perimenopausal, 1362
  dysfunctional, 337–339
  definition of, 329, 1358
  in adolescent, 338
  perimenopausal, 338
  treatment for, 339
  intermenstrual, 334–335
  definition of, 1358
  patterns of, terminology of, 1357–1359
  with hormone replacement therapy, 1350–1351
Uterine suspension, in chronic pelvic pain, 1422–1423
Uterosacral nerve ablation, in chronic pelvic pain, 1423
Uterus, bleeding from, adenocarcinoma and, 1352
  benign lesions and, 1364
  leiomyomas and, 1364
  malignant tumor and, 1364

Vacuum constriction devices, for impotence, 425–426
Vaginal discharge, with genital tract infections, 1274–1280
  bacterial vaginosis, 1274–1276
  Candida albicans, 1276
  cervicitis, 1277–1280
  Trichomonas vaginalis, 1276–1277
Vaginismus, psychosexual nature of, 1302–1303
Vaginosis, bacterial, 1274–1276
  clindamycin for, 853
  metronidazole for, 863
  treatment regimens for, 1275
Vancomycin, 817–831
  adverse effects of, 540
  allergy to, alternatives for, 941
  antibacterial activity of, teicoplanin vs, 835
  antimicrobial spectrum of, 817–818
  avoidance of, indications for, 828
  clinical spectrum of, 819
  clinical use of, 826–828
Vancomycin (Continued)
concentration in lower respiratory system, 586
concentration-independent killing by, 489
concentrations in body fluids, 823
drug interactions with, 825–826
elimination of, 821–822
for infection in immunocompromised host, 572–574
in renal failure, dosing of, 921
peculiarities of, 925
laboratory monitoring of, 544–545
pharmacokinetics of, 820–823
in hepatic disease, 910
resistance potential of, 818–820
safety profile of, 823–825
side effects of, 825
structure of, 834
therapeutic alternatives to, 828
Vascular disease, and impotence, 421
treatment of, 424
Vascular manifestations, in infective endocarditis, 1219
Vasectomy, for surgical sterilization, 1379–1380
Vasodilators, direct-acting, for heart failure, 1180–1181
Vasovagal syncope, management of, 1166–1167
pathophysiology of, in upright tilt testing, 1162
Vegetations, in infective endocarditis, echocardiography of, 1220–1223
Venous disease, and impotence, 421–422
Venous insufficiency, chronic, classification of, 443
unilateral leg swelling in, 441–442
Venous malformations, congenital, and unilateral leg swelling, 445
Venous obstruction/thrombosis, catecholamine-mediated, and bilateral massive adrenal hemorrhage, 112
Venous thrombosis, deep, acute, unilateral leg swelling in, 438–439
Ventricular premature beats, frequency vs mortality with, 1098
present trials of, 1098–1101
prognosis in, 1097–1098
recommendations concerning, 1101
Ventricular tachyarrhythmias, approaches to, 1097–1120
Ventricular tachycardia, idiopathic, catheter ablation for, 1111–1113
origins of, 1112–1113
nonsustained, 1101–1106
in coronary artery disease, 1101–1103
in hypertrophic cardiomyopathy, 1104–1105
in idiopathic dilated cardiomyopathy, 1103–1104
in valvular heart disease, 1105
without structural heart disease, 1105–1106
sustained, 1106–1115
catheter ablation in, 1109–1114. See also Catheter ablation.
devices for, 1108–1109
drug therapy for, 1106–1107
treatment recommendations for, 1114
Verapamil, cardiovascular actions of, 1075
for atrial fibrillation, 1139
for cluster headache prophylaxis, 276
for coronary artery disease with concomitant medical conditions, 1077
Vertebral disk, abnormalities of, incidence of, 238
herniation of, and low back pain, 235
Vesnarinone, for heart failure, studies of, 1177
Viral infection, and chronic fatigue syndrome, 322–323
Visceral sensation, altered, in irritable bowel syndrome, 376
Visual acuity, decreased, with Graves’s ophthalmopathy, 197, 201–202
Visual field test, with Graves’s ophthalmopathy, 204
Vitamin(s), intake of, as coronary risk factor, 958–959
Vitamin B$_6$, for premenstrual syndrome, 1468
Vitamin D, deficiency/resistance of, and hypocalcemia, 99
preparations of, 102
supplementation with, for hypocalcemia, 100
Vitamin E, for premenstrual syndrome, 1468
Vitamin K deficiency, and uterine bleeding, 1363
Volume of distribution, of antibiotics, 481
of drugs, in hepatic disease, 897–898
Volume reexpansion, in hypercalcemic crisis, 84
Water intoxication, and euvolemic hyponatremia, 161
Weight loss, involuntary, 299–313
age-related factors in, 306
and infection, 302
approach to patient with, 309–310
causes of, 303–308
medical, 303–306
neurologic, 306
psychiatric/behavioral, 307–308
social, 307
studies regarding, 308–309
diagnostic testing in, 310
management of, 310–311
mechanisms and consequences of, 300–303
significance of, 299–300
White blood cell labeling, in intra-abdominal sepsis, 604–605
Wolff-Parkinson-White syndrome, atrioventricular reciprocating tachycardia in, 1122
Women, genital tract infections in, 1271–1298. See also Genital tract.

Xamoterol, for heart failure, studies of, 1175
Xanthomonas maltophilia, antibiotic susceptibility of, 681

Yeast infections, on Papanicolaou smear, management in, 353
Yohimbine, for impotence, 427–428

Zidovudine, in hepatic disease, pharmacokinetics of, 904–905